id	sid	tid	token	lemma	pos
dti-1367	1	1	https://doi.org/10.1177/1177392817737515	https://doi.org/10.1177/1177392817737515	NOUN
dti-1367	1	2	drug	drug	NOUN
dti-1367	1	3	target	target	NOUN
dti-1367	1	4	insights	insight	NOUN
dti-1367	1	5	volume	volume	VERB
dti-1367	1	6	11	11	NUM
dti-1367	1	7	:	:	PUNCT
dti-1367	1	8	1–3	1–3	NUM
dti-1367	1	9	©	©	ADP
dti-1367	1	10	the	the	DET
dti-1367	1	11	author(s	author(s	NOUN
dti-1367	1	12	)	)	PUNCT
dti-1367	1	13	2017	2017	NUM
dti-1367	1	14	reprints	reprint	NOUN
dti-1367	1	15	and	and	CCONJ
dti-1367	1	16	permissions	permission	NOUN
dti-1367	1	17	:	:	PUNCT
dti-1367	2	1	sagepub.co.uk/journalspermissions.nav	sagepub.co.uk/journalspermissions.nav	PROPN
dti-1367	2	2	doi	doi	PROPN
dti-1367	2	3	:	:	PUNCT
dti-1367	2	4	10.1177/1177392817737515	10.1177/1177392817737515	NUM
dti-1367	2	5	creative	creative	ADJ
dti-1367	2	6	commons	common	NOUN
dti-1367	2	7	non	non	ADJ
dti-1367	2	8	commercial	commercial	PROPN
dti-1367	2	9	cc	cc	PROPN
dti-1367	2	10	by	by	ADP
dti-1367	2	11	-	-	PUNCT
dti-1367	2	12	nc	nc	PROPN
dti-1367	2	13	:	:	PUNCT
dti-1367	2	14	this	this	DET
dti-1367	2	15	article	article	NOUN
dti-1367	2	16	is	be	AUX
dti-1367	2	17	distributed	distribute	VERB
dti-1367	2	18	under	under	ADP
dti-1367	2	19	the	the	DET
dti-1367	2	20	terms	term	NOUN
dti-1367	2	21	of	of	ADP
dti-1367	2	22	the	the	DET
dti-1367	2	23	creative	creative	ADJ
dti-1367	2	24	commons	common	NOUN
dti-1367	2	25	attribution	attribution	NOUN
dti-1367	2	26	-	-	PUNCT
dti-1367	2	27	noncommercial	noncommercial	ADJ
dti-1367	2	28	4.0	4.0	NUM
dti-1367	2	29	license	license	NOUN
dti-1367	2	30	(	(	PUNCT
dti-1367	2	31	http://www.creativecommons.org/licenses/by-nc/4.0/	http://www.creativecommons.org/licenses/by-nc/4.0/	PROPN
dti-1367	2	32	)	)	PUNCT
dti-1367	2	33	which	which	PRON
dti-1367	2	34	permits	permit	VERB
dti-1367	2	35	non	non	ADJ
dti-1367	2	36	-	-	ADJ
dti-1367	2	37	commercial	commercial	ADJ
dti-1367	2	38	use	use	NOUN
dti-1367	2	39	,	,	PUNCT
dti-1367	2	40	reproduction	reproduction	NOUN
dti-1367	2	41	and	and	CCONJ
dti-1367	2	42	distribution	distribution	NOUN
dti-1367	2	43	of	of	ADP
dti-1367	2	44	the	the	DET
dti-1367	2	45	work	work	NOUN
dti-1367	2	46	without	without	ADP
dti-1367	2	47	further	further	ADJ
dti-1367	2	48	permission	permission	NOUN
dti-1367	2	49	provided	provide	VERB
dti-1367	2	50	the	the	DET
dti-1367	2	51	original	original	ADJ
dti-1367	2	52	work	work	NOUN
dti-1367	2	53	is	be	AUX
dti-1367	2	54	attributed	attribute	VERB
dti-1367	2	55	as	as	ADP
dti-1367	2	56	specified	specify	VERB
dti-1367	2	57	on	on	ADP
dti-1367	2	58	the	the	DET
dti-1367	2	59	sage	sage	NOUN
dti-1367	2	60	and	and	CCONJ
dti-1367	2	61	open	open	ADJ
dti-1367	2	62	access	access	NOUN
dti-1367	2	63	pages	page	NOUN
dti-1367	2	64	(	(	PUNCT
dti-1367	2	65	https://us.sagepub.com/en-us/nam/open-access-at-sage	https://us.sagepub.com/en-us/nam/open-access-at-sage	NOUN
dti-1367	2	66	)	)	PUNCT
dti-1367	2	67	.	.	PUNCT
dti-1367	3	1	background	background	NOUN
dti-1367	3	2	and	and	CCONJ
dti-1367	3	3	introduction	introduction	NOUN
dti-1367	3	4	in	in	ADP
dti-1367	3	5	march	march	PROPN
dti-1367	3	6	2017	2017	NUM
dti-1367	3	7	,	,	PUNCT
dti-1367	3	8	ocrelizumab	ocrelizumab	X
dti-1367	3	9	(	(	PUNCT
dti-1367	3	10	ocr	ocr	NOUN
dti-1367	3	11	)	)	PUNCT
dti-1367	3	12	was	be	AUX
dti-1367	3	13	approved	approve	VERB
dti-1367	3	14	by	by	ADP
dti-1367	3	15	the	the	DET
dti-1367	3	16	food	food	NOUN
dti-1367	3	17	and	and	CCONJ
dti-1367	3	18	drug	drug	PROPN
dti-1367	3	19	administration	administration	PROPN
dti-1367	3	20	(	(	PUNCT
dti-1367	3	21	fda	fda	PROPN
dti-1367	3	22	)	)	PUNCT
dti-1367	3	23	for	for	ADP
dti-1367	3	24	the	the	DET
dti-1367	3	25	treatment	treatment	NOUN
dti-1367	3	26	of	of	ADP
dti-1367	3	27	relapsing	relapse	VERB
dti-1367	3	28	forms	form	NOUN
dti-1367	3	29	of	of	ADP
dti-1367	3	30	multiple	multiple	ADJ
dti-1367	3	31	sclerosis	sclerosis	NOUN
dti-1367	3	32	(	(	PUNCT
dti-1367	3	33	ms	ms	NOUN
dti-1367	3	34	)	)	PUNCT
dti-1367	3	35	and	and	CCONJ
dti-1367	3	36	primary	primary	ADJ
dti-1367	3	37	-	-	PUNCT
dti-1367	3	38	progressive	progressive	ADJ
dti-1367	3	39	multiple	multiple	ADJ
dti-1367	3	40	sclerosis	sclerosis	NOUN
dti-1367	3	41	.	.	PUNCT
dti-1367	4	1	it	it	PRON
dti-1367	4	2	is	be	AUX
dti-1367	4	3	a	a	DET
dti-1367	4	4	humanized	humanize	VERB
dti-1367	4	5	anti	anti	ADJ
dti-1367	4	6	-	-	ADJ
dti-1367	4	7	cd20	cd20	ADJ
dti-1367	4	8	monoclonal	monoclonal	NOUN
dti-1367	4	9	antibody	antibody	NOUN
dti-1367	4	10	(	(	PUNCT
dti-1367	4	11	mab	mab	NOUN
dti-1367	4	12	)	)	PUNCT
dti-1367	4	13	molecule	molecule	NOUN
dti-1367	4	14	that	that	PRON
dti-1367	4	15	leads	lead	VERB
dti-1367	4	16	the	the	DET
dti-1367	4	17	mab	mab	PROPN
dti-1367	4	18	revolution	revolution	NOUN
dti-1367	4	19	in	in	ADP
dti-1367	4	20	the	the	DET
dti-1367	4	21	treatment	treatment	NOUN
dti-1367	4	22	of	of	ADP
dti-1367	4	23	ms	ms	PROPN
dti-1367	4	24	.	.	PROPN
dti-1367	4	25	to	to	PART
dti-1367	4	26	understand	understand	VERB
dti-1367	4	27	ocr	ocr	PROPN
dti-1367	4	28	and	and	CCONJ
dti-1367	4	29	its	its	PRON
dti-1367	4	30	pharmacodynamics	pharmacodynamic	NOUN
dti-1367	4	31	,	,	PUNCT
dti-1367	4	32	a	a	DET
dti-1367	4	33	closer	close	ADJ
dti-1367	4	34	look	look	NOUN
dti-1367	4	35	at	at	ADP
dti-1367	4	36	rituximab	rituximab	NOUN
dti-1367	4	37	(	(	PUNCT
dti-1367	4	38	rtx	rtx	PROPN
dti-1367	4	39	)	)	PUNCT
dti-1367	4	40	helps	help	VERB
dti-1367	4	41	one	one	NUM
dti-1367	4	42	to	to	PART
dti-1367	4	43	decode	decode	VERB
dti-1367	4	44	ocr	ocr	PROPN
dti-1367	4	45	dosing	dosing	NOUN
dti-1367	4	46	.	.	PUNCT
dti-1367	5	1	published	publish	VERB
dti-1367	5	2	literature	literature	NOUN
dti-1367	5	3	suggests	suggest	VERB
dti-1367	5	4	that	that	SCONJ
dti-1367	5	5	rtx	rtx	PROPN
dti-1367	5	6	is	be	AUX
dti-1367	5	7	a	a	DET
dti-1367	5	8	chimeric	chimeric	ADJ
dti-1367	5	9	(	(	PUNCT
dti-1367	5	10	human/	human/	NUM
dti-1367	5	11	murine	murine	NOUN
dti-1367	5	12	)	)	PUNCT
dti-1367	5	13	mab	mab	NOUN
dti-1367	5	14	directed	direct	VERB
dti-1367	5	15	against	against	ADP
dti-1367	5	16	the	the	DET
dti-1367	5	17	human	human	PROPN
dti-1367	5	18	cd20	cd20	PROPN
dti-1367	5	19	molecule1	molecule1	PROPN
dti-1367	5	20	and	and	CCONJ
dti-1367	5	21	promotes	promote	VERB
dti-1367	5	22	cytotoxicity	cytotoxicity	NOUN
dti-1367	5	23	and	and	CCONJ
dti-1367	5	24	apoptosis	apoptosis	NOUN
dti-1367	5	25	.	.	PUNCT
dti-1367	6	1	it	it	PRON
dti-1367	6	2	was	be	AUX
dti-1367	6	3	approved	approve	VERB
dti-1367	6	4	by	by	ADP
dti-1367	6	5	the	the	DET
dti-1367	6	6	fda	fda	PROPN
dti-1367	6	7	for	for	ADP
dti-1367	6	8	the	the	DET
dti-1367	6	9	treatment	treatment	NOUN
dti-1367	6	10	of	of	ADP
dti-1367	6	11	rheumatoid	rheumatoid	NOUN
dti-1367	6	12	arthritis	arthritis	NOUN
dti-1367	6	13	(	(	PUNCT
dti-1367	6	14	ra	ra	NOUN
dti-1367	6	15	)	)	PUNCT
dti-1367	6	16	in	in	ADP
dti-1367	6	17	2006	2006	NUM
dti-1367	6	18	and	and	CCONJ
dti-1367	6	19	was	be	AUX
dti-1367	6	20	the	the	DET
dti-1367	6	21	first	first	ADJ
dti-1367	6	22	therapeutic	therapeutic	ADJ
dti-1367	6	23	b	b	NOUN
dti-1367	6	24	-	-	PUNCT
dti-1367	6	25	cell	cell	NOUN
dti-1367	6	26	–	–	PUNCT
dti-1367	6	27	depleting	deplete	VERB
dti-1367	6	28	chimeric	chimeric	ADJ
dti-1367	6	29	mab	mab	NOUN
dti-1367	6	30	to	to	PART
dti-1367	6	31	be	be	AUX
dti-1367	6	32	used	use	VERB
dti-1367	6	33	in	in	ADP
dti-1367	6	34	ms	ms	NOUN
dti-1367	6	35	with	with	ADP
dti-1367	6	36	success	success	NOUN
dti-1367	6	37	.	.	PUNCT
dti-1367	7	1	diseases	disease	NOUN
dti-1367	7	2	such	such	ADJ
dti-1367	7	3	as	as	ADP
dti-1367	7	4	ms	ms	PROPN
dti-1367	7	5	,	,	PUNCT
dti-1367	7	6	ra	ra	PROPN
dti-1367	7	7	,	,	PUNCT
dti-1367	7	8	neuromyelitis	neuromyelitis	PROPN
dti-1367	7	9	optica	optica	PROPN
dti-1367	7	10	/	/	SYM
dti-1367	7	11	neuromyelitis	neuromyelitis	PROPN
dti-1367	7	12	optica	optica	PROPN
dti-1367	7	13	spectrum	spectrum	NOUN
dti-1367	7	14	disorder	disorder	NOUN
dti-1367	7	15	(	(	PUNCT
dti-1367	7	16	nmo/	nmo/	NOUN
dti-1367	7	17	nmosd	nmosd	ADJ
dti-1367	7	18	)	)	PUNCT
dti-1367	7	19	,	,	PUNCT
dti-1367	7	20	systemic	systemic	ADJ
dti-1367	7	21	lupus	lupus	PROPN
dti-1367	7	22	erythematosus	erythematosus	PROPN
dti-1367	7	23	,	,	PUNCT
dti-1367	7	24	peripheral	peripheral	ADJ
dti-1367	7	25	neuropathies	neuropathy	NOUN
dti-1367	7	26	,	,	PUNCT
dti-1367	7	27	antimyelin	antimyelin	NOUN
dti-1367	7	28	-	-	PUNCT
dti-1367	7	29	associated	associate	VERB
dti-1367	7	30	glycoprotein	glycoprotein	NOUN
dti-1367	7	31	neuropathy	neuropathy	ADJ
dti-1367	7	32	,	,	PUNCT
dti-1367	7	33	chronic	chronic	ADJ
dti-1367	7	34	inflammatory	inflammatory	ADJ
dti-1367	7	35	demyelinating	demyelinate	VERB
dti-1367	7	36	polyneuropathy	polyneuropathy	NOUN
dti-1367	7	37	,	,	PUNCT
dti-1367	7	38	subacute	subacute	VERB
dti-1367	7	39	ataxic	ataxic	ADJ
dti-1367	7	40	neuropathy	neuropathy	ADJ
dti-1367	7	41	without	without	ADP
dti-1367	7	42	paraproteinemia	paraproteinemia	NOUN
dti-1367	7	43	,	,	PUNCT
dti-1367	7	44	myasthenia	myasthenia	NOUN
dti-1367	7	45	gravis	gravis	NOUN
dti-1367	7	46	,	,	PUNCT
dti-1367	7	47	opsoclonus	opsoclonus	ADJ
dti-1367	7	48	-	-	PUNCT
dti-1367	7	49	myoclonus	myoclonus	NOUN
dti-1367	7	50	syndrome	syndrome	NOUN
dti-1367	7	51	,	,	PUNCT
dti-1367	7	52	and	and	CCONJ
dti-1367	7	53	inflammatory	inflammatory	ADJ
dti-1367	7	54	myopathies	myopathy	NOUN
dti-1367	7	55	have	have	AUX
dti-1367	7	56	been	be	AUX
dti-1367	7	57	treated	treat	VERB
dti-1367	7	58	using	use	VERB
dti-1367	7	59	anti	anti	ADJ
dti-1367	7	60	-	-	ADJ
dti-1367	7	61	cd20	cd20	ADJ
dti-1367	7	62	mabs	mab	NOUN
dti-1367	7	63	.	.	PUNCT
dti-1367	8	1	both	both	PRON
dti-1367	8	2	ocr	ocr	PROPN
dti-1367	8	3	and	and	CCONJ
dti-1367	8	4	rtx	rtx	NOUN
dti-1367	8	5	bind	bind	NOUN
dti-1367	8	6	to	to	ADP
dti-1367	8	7	an	an	DET
dti-1367	8	8	extracellular	extracellular	ADJ
dti-1367	8	9	cd20	cd20	PROPN
dti-1367	8	10	epitope	epitope	NOUN
dti-1367	8	11	on	on	ADP
dti-1367	8	12	b	b	NOUN
dti-1367	8	13	cells	cell	NOUN
dti-1367	8	14	whose	whose	DET
dti-1367	8	15	binding	bind	VERB
dti-1367	8	16	site	site	NOUN
dti-1367	8	17	overlaps	overlap	VERB
dti-1367	8	18	between	between	ADP
dti-1367	8	19	each	each	DET
dti-1367	8	20	drug	drug	NOUN
dti-1367	8	21	.	.	PUNCT
dti-1367	9	1	following	follow	VERB
dti-1367	9	2	cd19	cd19	PROPN
dti-1367	9	3	cell	cell	NOUN
dti-1367	9	4	counts	count	NOUN
dti-1367	9	5	as	as	ADP
dti-1367	9	6	a	a	DET
dti-1367	9	7	surrogate	surrogate	ADJ
dti-1367	9	8	marker	marker	NOUN
dti-1367	9	9	for	for	ADP
dti-1367	9	10	cd20	cd20	PROPN
dti-1367	9	11	cells	cell	NOUN
dti-1367	9	12	in	in	ADP
dti-1367	9	13	the	the	DET
dti-1367	9	14	peripheral	peripheral	ADJ
dti-1367	9	15	blood	blood	NOUN
dti-1367	9	16	in	in	ADP
dti-1367	9	17	patients	patient	NOUN
dti-1367	9	18	with	with	ADP
dti-1367	9	19	ra	ra	PROPN
dti-1367	9	20	,	,	PUNCT
dti-1367	9	21	nmosd	nmosd	NOUN
dti-1367	9	22	,	,	PUNCT
dti-1367	9	23	and	and	CCONJ
dti-1367	9	24	ms	ms	NOUN
dti-1367	9	25	on	on	ADP
dti-1367	9	26	rtx	rtx	PROPN
dti-1367	9	27	therapy	therapy	NOUN
dti-1367	9	28	helps	help	VERB
dti-1367	9	29	us	we	PRON
dti-1367	9	30	understand	understand	VERB
dti-1367	9	31	how	how	SCONJ
dti-1367	9	32	the	the	DET
dti-1367	9	33	dosing	dosing	NOUN
dti-1367	9	34	of	of	ADP
dti-1367	9	35	ocr	ocr	PROPN
dti-1367	9	36	dosing	dose	VERB
dti-1367	9	37	may	may	AUX
dti-1367	9	38	be	be	AUX
dti-1367	9	39	optimized	optimize	VERB
dti-1367	9	40	in	in	ADP
dti-1367	9	41	the	the	DET
dti-1367	9	42	treatment	treatment	NOUN
dti-1367	9	43	of	of	ADP
dti-1367	9	44	ms	ms	PROPN
dti-1367	9	45	.	.	PROPN
dti-1367	9	46	in	in	ADP
dti-1367	9	47	general	general	ADJ
dti-1367	9	48	,	,	PUNCT
dti-1367	9	49	rtx	rtx	PROPN
dti-1367	9	50	treatment	treatment	NOUN
dti-1367	9	51	produces	produce	VERB
dti-1367	9	52	a	a	DET
dti-1367	9	53	rapid	rapid	ADJ
dti-1367	9	54	depletion	depletion	NOUN
dti-1367	9	55	of	of	ADP
dti-1367	9	56	cd20	cd20	PROPN
dti-1367	9	57	cells	cell	NOUN
dti-1367	9	58	from	from	ADP
dti-1367	9	59	the	the	DET
dti-1367	9	60	circulation	circulation	NOUN
dti-1367	9	61	but	but	CCONJ
dti-1367	9	62	does	do	AUX
dti-1367	9	63	not	not	PART
dti-1367	9	64	directly	directly	ADV
dti-1367	9	65	target	target	VERB
dti-1367	9	66	pro	pro	ADJ
dti-1367	9	67	-	-	ADJ
dti-1367	9	68	b	b	ADJ
dti-1367	9	69	cells	cell	NOUN
dti-1367	9	70	,	,	PUNCT
dti-1367	9	71	their	their	PRON
dti-1367	9	72	precursors	precursor	NOUN
dti-1367	9	73	,	,	PUNCT
dti-1367	9	74	or	or	CCONJ
dti-1367	9	75	plasma	plasma	NOUN
dti-1367	9	76	cells.2–3	cells.2–3	NOUN
dti-1367	9	77	as	as	SCONJ
dti-1367	9	78	rtx	rtx	PROPN
dti-1367	9	79	interferes	interfere	VERB
dti-1367	9	80	with	with	ADP
dti-1367	9	81	flow	flow	NOUN
dti-1367	9	82	cytometric	cytometric	ADJ
dti-1367	9	83	analysis	analysis	NOUN
dti-1367	9	84	of	of	ADP
dti-1367	9	85	cd20	cd20	PROPN
dti-1367	9	86	cells	cell	NOUN
dti-1367	9	87	,	,	PUNCT
dti-1367	9	88	cd19	cd19	PROPN
dti-1367	9	89	cells	cell	NOUN
dti-1367	9	90	,	,	PUNCT
dti-1367	9	91	which	which	PRON
dti-1367	9	92	carry	carry	VERB
dti-1367	9	93	a	a	DET
dti-1367	9	94	similar	similar	ADJ
dti-1367	9	95	expression	expression	NOUN
dti-1367	9	96	profile	profile	NOUN
dti-1367	9	97	,	,	PUNCT
dti-1367	9	98	are	be	AUX
dti-1367	9	99	typically	typically	ADV
dti-1367	9	100	used	use	VERB
dti-1367	9	101	as	as	ADP
dti-1367	9	102	surrogate	surrogate	ADJ
dti-1367	9	103	markers	marker	NOUN
dti-1367	9	104	to	to	PART
dti-1367	9	105	schedule	schedule	VERB
dti-1367	9	106	reinfusion	reinfusion	NOUN
dti-1367	9	107	based	base	VERB
dti-1367	9	108	on	on	ADP
dti-1367	9	109	cd19	cd19	PROPN
dti-1367	9	110	cell	cell	NOUN
dti-1367	9	111	counts	count	NOUN
dti-1367	9	112	.	.	PUNCT
dti-1367	10	1	it	it	PRON
dti-1367	10	2	is	be	AUX
dti-1367	10	3	thought	think	VERB
dti-1367	10	4	that	that	SCONJ
dti-1367	10	5	rtx	rtx	NOUN
dti-1367	10	6	binding	bind	VERB
dti-1367	10	7	to	to	ADP
dti-1367	10	8	cd20	cd20	PROPN
dti-1367	10	9	enables	enable	VERB
dti-1367	10	10	cells	cell	NOUN
dti-1367	10	11	to	to	PART
dti-1367	10	12	mediate	mediate	VERB
dti-1367	10	13	trogocytosis	trogocytosis	NOUN
dti-1367	10	14	or	or	CCONJ
dti-1367	10	15	“	"	PUNCT
dti-1367	10	16	shaving	shaving	NOUN
dti-1367	10	17	”	"	PUNCT
dti-1367	10	18	causing	cause	VERB
dti-1367	10	19	internalization	internalization	NOUN
dti-1367	10	20	of	of	ADP
dti-1367	10	21	the	the	DET
dti-1367	10	22	rtx	rtx	PROPN
dti-1367	10	23	-	-	PUNCT
dti-1367	10	24	cd20	cd20	PROPN
dti-1367	10	25	complex	complex	ADJ
dti-1367	10	26	and	and	CCONJ
dti-1367	10	27	accompanying	accompany	VERB
dti-1367	10	28	cell	cell	NOUN
dti-1367	10	29	membrane	membrane	NOUN
dti-1367	10	30	through	through	ADP
dti-1367	10	31	an	an	DET
dti-1367	10	32	fcγ	fcγ	NOUN
dti-1367	10	33	receptor	receptor	NOUN
dti-1367	10	34	–	–	PUNCT
dti-1367	10	35	dependent	dependent	ADJ
dti-1367	10	36	mechanism4–5	mechanism4–5	PROPN
dti-1367	10	37	—	—	PUNCT
dti-1367	10	38	this	this	DET
dti-1367	10	39	process	process	NOUN
dti-1367	10	40	is	be	AUX
dti-1367	10	41	thought	think	VERB
dti-1367	10	42	to	to	PART
dti-1367	10	43	interfere	interfere	VERB
dti-1367	10	44	with	with	ADP
dti-1367	10	45	the	the	DET
dti-1367	10	46	flow	flow	NOUN
dti-1367	10	47	cytometric	cytometric	ADJ
dti-1367	10	48	analysis	analysis	NOUN
dti-1367	10	49	of	of	ADP
dti-1367	10	50	cd20	cd20	PROPN
dti-1367	10	51	cells	cell	NOUN
dti-1367	10	52	,	,	PUNCT
dti-1367	10	53	and	and	CCONJ
dti-1367	10	54	therefore	therefore	ADV
dti-1367	10	55	,	,	PUNCT
dti-1367	10	56	cd19	cd19	PROPN
dti-1367	10	57	cell	cell	NOUN
dti-1367	10	58	counts	count	NOUN
dti-1367	10	59	serve	serve	VERB
dti-1367	10	60	as	as	ADP
dti-1367	10	61	the	the	DET
dti-1367	10	62	surrogate	surrogate	ADJ
dti-1367	10	63	marker	marker	NOUN
dti-1367	10	64	to	to	PART
dti-1367	10	65	monitor	monitor	VERB
dti-1367	10	66	treatment	treatment	NOUN
dti-1367	10	67	efficiency	efficiency	NOUN
dti-1367	10	68	of	of	ADP
dti-1367	10	69	anti	anti	ADJ
dti-1367	10	70	-	-	ADJ
dti-1367	10	71	cd20	cd20	ADJ
dti-1367	10	72	cell	cell	NOUN
dti-1367	10	73	therapies	therapy	NOUN
dti-1367	10	74	.	.	PUNCT
dti-1367	11	1	the	the	DET
dti-1367	11	2	depth	depth	NOUN
dti-1367	11	3	of	of	ADP
dti-1367	11	4	b	b	NOUN
dti-1367	11	5	-	-	PUNCT
dti-1367	11	6	cell	cell	NOUN
dti-1367	11	7	depletion	depletion	NOUN
dti-1367	11	8	is	be	AUX
dti-1367	11	9	variable	variable	ADJ
dti-1367	11	10	among	among	ADP
dti-1367	11	11	patients	patient	NOUN
dti-1367	11	12	,	,	PUNCT
dti-1367	11	13	but	but	CCONJ
dti-1367	11	14	restoration	restoration	NOUN
dti-1367	11	15	of	of	ADP
dti-1367	11	16	the	the	DET
dti-1367	11	17	b	b	NOUN
dti-1367	11	18	-	-	PUNCT
dti-1367	11	19	cell	cell	NOUN
dti-1367	11	20	repertoire	repertoire	NOUN
dti-1367	11	21	takes	take	VERB
dti-1367	11	22	between	between	ADP
dti-1367	11	23	9	9	NUM
dti-1367	11	24	and	and	CCONJ
dti-1367	11	25	12	12	NUM
dti-1367	11	26	months	month	NOUN
dti-1367	11	27	from	from	ADP
dti-1367	11	28	the	the	DET
dti-1367	11	29	last	last	ADJ
dti-1367	11	30	perfusion	perfusion	NOUN
dti-1367	11	31	of	of	ADP
dti-1367	11	32	rtx.6	rtx.6	PROPN
dti-1367	11	33	in	in	ADP
dti-1367	11	34	patients	patient	NOUN
dti-1367	11	35	with	with	ADP
dti-1367	11	36	ra	ra	PROPN
dti-1367	11	37	,	,	PUNCT
dti-1367	11	38	treatment	treatment	NOUN
dti-1367	11	39	with	with	ADP
dti-1367	11	40	rtx	rtx	PROPN
dti-1367	11	41	induces	induce	VERB
dti-1367	11	42	depletion	depletion	NOUN
dti-1367	11	43	of	of	ADP
dti-1367	11	44	peripheral	peripheral	ADJ
dti-1367	11	45	b	b	NOUN
dti-1367	11	46	lymphocytes	lymphocyte	NOUN
dti-1367	11	47	,	,	PUNCT
dti-1367	11	48	with	with	ADP
dti-1367	11	49	many	many	ADJ
dti-1367	11	50	patients	patient	NOUN
dti-1367	11	51	demonstrating	demonstrate	VERB
dti-1367	11	52	near	near	ADP
dti-1367	11	53	complete	complete	ADJ
dti-1367	11	54	depletion	depletion	NOUN
dti-1367	11	55	(	(	PUNCT
dti-1367	11	56	cd19	cd19	PROPN
dti-1367	11	57	counts	count	NOUN
dti-1367	11	58	are	be	AUX
dti-1367	11	59	<	<	X
dti-1367	11	60	20	20	NUM
dti-1367	11	61	cells	cell	NOUN
dti-1367	11	62	/	/	SYM
dti-1367	11	63	μl	μl	ADP
dti-1367	11	64	or	or	CCONJ
dti-1367	11	65	below	below	ADP
dti-1367	11	66	the	the	DET
dti-1367	11	67	lower	low	ADJ
dti-1367	11	68	limit	limit	NOUN
dti-1367	11	69	of	of	ADP
dti-1367	11	70	quantification	quantification	NOUN
dti-1367	11	71	)	)	PUNCT
dti-1367	11	72	within	within	ADP
dti-1367	11	73	2	2	NUM
dti-1367	11	74	weeks	week	NOUN
dti-1367	11	75	after	after	ADP
dti-1367	11	76	receiving	receive	VERB
dti-1367	11	77	the	the	DET
dti-1367	11	78	first	first	ADJ
dti-1367	11	79	dose	dose	NOUN
dti-1367	11	80	of	of	ADP
dti-1367	11	81	the	the	DET
dti-1367	11	82	drug	drug	NOUN
dti-1367	11	83	.	.	PUNCT
dti-1367	12	1	some	some	DET
dti-1367	12	2	patients	patient	NOUN
dti-1367	12	3	show	show	VERB
dti-1367	12	4	peripheral	peripheral	ADJ
dti-1367	12	5	b	b	NOUN
dti-1367	12	6	-	-	PUNCT
dti-1367	12	7	cell	cell	NOUN
dti-1367	12	8	depletion	depletion	NOUN
dti-1367	12	9	that	that	PRON
dti-1367	12	10	lasts	last	VERB
dti-1367	12	11	for	for	ADP
dti-1367	12	12	at	at	ADV
dti-1367	12	13	least	least	ADV
dti-1367	12	14	6	6	NUM
dti-1367	12	15	months	month	NOUN
dti-1367	12	16	.	.	PUNCT
dti-1367	13	1	up	up	ADP
dti-1367	13	2	to	to	ADP
dti-1367	13	3	~4	~4	NOUN
dti-1367	13	4	%	%	NOUN
dti-1367	13	5	of	of	ADP
dti-1367	13	6	patients	patient	NOUN
dti-1367	13	7	with	with	ADP
dti-1367	13	8	ra	ra	PROPN
dti-1367	13	9	had	have	AUX
dti-1367	13	10	prolonged	prolong	VERB
dti-1367	13	11	peripheral	peripheral	ADJ
dti-1367	13	12	b	b	NOUN
dti-1367	13	13	-	-	PUNCT
dti-1367	13	14	cell	cell	NOUN
dti-1367	13	15	depletion	depletion	NOUN
dti-1367	13	16	lasting	last	VERB
dti-1367	13	17	more	more	ADJ
dti-1367	13	18	than	than	ADP
dti-1367	13	19	3	3	NUM
dti-1367	13	20	years	year	NOUN
dti-1367	13	21	after	after	ADP
dti-1367	13	22	a	a	DET
dti-1367	13	23	single	single	ADJ
dti-1367	13	24	course	course	NOUN
dti-1367	13	25	of	of	ADP
dti-1367	13	26	rtx	rtx	PROPN
dti-1367	13	27	.	.	PUNCT
dti-1367	14	1	equally	equally	ADV
dti-1367	14	2	important	important	ADJ
dti-1367	14	3	,	,	PUNCT
dti-1367	14	4	some	some	DET
dti-1367	14	5	patients	patient	NOUN
dti-1367	14	6	may	may	AUX
dti-1367	14	7	need	need	VERB
dti-1367	14	8	more	more	ADJ
dti-1367	14	9	infusions	infusion	NOUN
dti-1367	14	10	than	than	ADP
dti-1367	14	11	a	a	DET
dti-1367	14	12	6	6	NUM
dti-1367	14	13	-	-	PUNCT
dti-1367	14	14	month	month	NOUN
dti-1367	14	15	re	re	NOUN
dti-1367	14	16	-	-	NOUN
dti-1367	14	17	administration	administration	NOUN
dti-1367	14	18	schedule	schedule	NOUN
dti-1367	14	19	.	.	PUNCT
dti-1367	15	1	the	the	DET
dti-1367	15	2	reconstitution	reconstitution	NOUN
dti-1367	15	3	of	of	ADP
dti-1367	15	4	peripheral	peripheral	ADJ
dti-1367	15	5	blood	blood	NOUN
dti-1367	15	6	b	b	NOUN
dti-1367	15	7	cells	cell	NOUN
dti-1367	15	8	after	after	SCONJ
dti-1367	15	9	rtx	rtx	NOUN
dti-1367	15	10	therapy	therapy	NOUN
dti-1367	15	11	in	in	ADP
dti-1367	15	12	patients	patient	NOUN
dti-1367	15	13	with	with	ADP
dti-1367	15	14	ra	ra	PROPN
dti-1367	15	15	was	be	AUX
dti-1367	15	16	noted	note	VERB
dti-1367	15	17	after	after	ADP
dti-1367	15	18	a	a	DET
dti-1367	15	19	mean	mean	NOUN
dti-1367	15	20	of	of	ADP
dti-1367	15	21	8	8	NUM
dti-1367	15	22	months	month	NOUN
dti-1367	15	23	posttreatment.7	posttreatment.7	PROPN
dti-1367	15	24	anti	anti	ADJ
dti-1367	15	25	-	-	ADJ
dti-1367	15	26	cd20	cd20	ADJ
dti-1367	15	27	cell	cell	NOUN
dti-1367	15	28	therapies	therapy	NOUN
dti-1367	15	29	in	in	ADP
dti-1367	15	30	multiple	multiple	ADJ
dti-1367	15	31	sclerosis	sclerosis	NOUN
dti-1367	15	32	—	—	PUNCT
dti-1367	15	33	a	a	DET
dti-1367	15	34	fixed	fix	VERB
dti-1367	15	35	dosing	dose	VERB
dti-1367	15	36	schedule	schedule	NOUN
dti-1367	15	37	for	for	ADP
dti-1367	15	38	ocrelizumab	ocrelizumab	NOUN
dti-1367	15	39	is	be	AUX
dti-1367	16	1	overkill	overkill	ADV
dti-1367	16	2	jagannadha	jagannadha	PROPN
dti-1367	16	3	avasarala1,2	avasarala1,2	PROPN
dti-1367	16	4	1department	1department	NUM
dti-1367	16	5	of	of	ADP
dti-1367	16	6	medicine	medicine	NOUN
dti-1367	16	7	,	,	PUNCT
dti-1367	16	8	division	division	NOUN
dti-1367	16	9	of	of	ADP
dti-1367	16	10	neurology	neurology	NOUN
dti-1367	16	11	,	,	PUNCT
dti-1367	16	12	usc	usc	PROPN
dti-1367	16	13	school	school	NOUN
dti-1367	16	14	of	of	ADP
dti-1367	16	15	medicine	medicine	PROPN
dti-1367	16	16	greenville	greenville	PROPN
dti-1367	16	17	,	,	PUNCT
dti-1367	16	18	greenville	greenville	PROPN
dti-1367	16	19	,	,	PUNCT
dti-1367	16	20	sc	sc	PROPN
dti-1367	16	21	,	,	PUNCT
dti-1367	16	22	usa	usa	PROPN
dti-1367	16	23	.	.	PROPN
dti-1367	17	1	2department	2department	NUM
dti-1367	17	2	of	of	ADP
dti-1367	17	3	internal	internal	ADJ
dti-1367	17	4	medicine	medicine	NOUN
dti-1367	17	5	,	,	PUNCT
dti-1367	17	6	division	division	NOUN
dti-1367	17	7	of	of	ADP
dti-1367	17	8	neurology	neurology	NOUN
dti-1367	17	9	,	,	PUNCT
dti-1367	17	10	usc	usc	PROPN
dti-1367	17	11	school	school	NOUN
dti-1367	17	12	of	of	ADP
dti-1367	17	13	medicine	medicine	NOUN
dti-1367	17	14	and	and	CCONJ
dti-1367	17	15	umg	umg	NOUN
dti-1367	17	16	-	-	PUNCT
dti-1367	17	17	neuroscience	neuroscience	NOUN
dti-1367	17	18	associates	associate	NOUN
dti-1367	17	19	,	,	PUNCT
dti-1367	17	20	greenville	greenville	PROPN
dti-1367	17	21	,	,	PUNCT
dti-1367	17	22	sc	sc	PROPN
dti-1367	17	23	,	,	PUNCT
dti-1367	17	24	usa	usa	PROPN
dti-1367	17	25	.	.	PROPN
dti-1367	17	26	abstract	abstract	PROPN
dti-1367	17	27	:	:	PUNCT
dti-1367	17	28	anti	anti	ADJ
dti-1367	17	29	-	-	ADJ
dti-1367	17	30	cd	cd	ADJ
dti-1367	17	31	20	20	NUM
dti-1367	17	32	therapies	therapy	NOUN
dti-1367	17	33	have	have	AUX
dti-1367	17	34	found	find	VERB
dti-1367	17	35	significant	significant	ADJ
dti-1367	17	36	uses	use	NOUN
dti-1367	17	37	in	in	ADP
dti-1367	17	38	multiple	multiple	ADJ
dti-1367	17	39	sclerosis	sclerosis	NOUN
dti-1367	17	40	(	(	PUNCT
dti-1367	17	41	ms	ms	NOUN
dti-1367	17	42	)	)	PUNCT
dti-1367	17	43	.	.	PUNCT
dti-1367	18	1	based	base	VERB
dti-1367	18	2	singularly	singularly	ADV
dti-1367	18	3	on	on	ADP
dti-1367	18	4	the	the	DET
dti-1367	18	5	accumulated	accumulate	VERB
dti-1367	18	6	evidence	evidence	NOUN
dti-1367	18	7	with	with	ADP
dti-1367	18	8	the	the	DET
dti-1367	18	9	use	use	NOUN
dti-1367	18	10	of	of	ADP
dti-1367	18	11	rituximab	rituximab	NOUN
dti-1367	18	12	(	(	PUNCT
dti-1367	18	13	rtx	rtx	PROPN
dti-1367	18	14	;	;	PUNCT
dti-1367	18	15	rituxan	rituxan	NOUN
dti-1367	18	16	,	,	PUNCT
dti-1367	18	17	genentech	genentech	NOUN
dti-1367	18	18	,	,	PUNCT
dti-1367	18	19	and	and	CCONJ
dti-1367	18	20	biogen	biogen	PROPN
dti-1367	18	21	)	)	PUNCT
dti-1367	18	22	in	in	ADP
dti-1367	18	23	neuroimmunological	neuroimmunological	ADJ
dti-1367	18	24	diseases	disease	NOUN
dti-1367	18	25	,	,	PUNCT
dti-1367	18	26	ocrelizumab	ocrelizumab	NOUN
dti-1367	18	27	(	(	PUNCT
dti-1367	18	28	ocr	ocr	NOUN
dti-1367	18	29	;	;	PUNCT
dti-1367	18	30	ocrevus	ocrevus	PROPN
dti-1367	18	31	,	,	PUNCT
dti-1367	18	32	genentech	genentech	NOUN
dti-1367	18	33	)	)	PUNCT
dti-1367	18	34	was	be	AUX
dti-1367	18	35	developed	develop	VERB
dti-1367	18	36	as	as	ADP
dti-1367	18	37	a	a	DET
dti-1367	18	38	treatment	treatment	NOUN
dti-1367	18	39	option	option	NOUN
dti-1367	18	40	for	for	SCONJ
dti-1367	18	41	ms	ms	NOUN
dti-1367	18	42	and	and	CCONJ
dti-1367	18	43	selectively	selectively	ADV
dti-1367	18	44	targets	target	VERB
dti-1367	18	45	cd20	cd20	PROPN
dti-1367	18	46	b	b	PROPN
dti-1367	18	47	cells	cell	NOUN
dti-1367	18	48	,	,	PUNCT
dti-1367	18	49	a	a	DET
dti-1367	18	50	cell	cell	NOUN
dti-1367	18	51	surface	surface	NOUN
dti-1367	18	52	antigen	antigen	NOUN
dti-1367	18	53	found	find	VERB
dti-1367	18	54	on	on	ADP
dti-1367	18	55	pre	pre	ADJ
dti-1367	18	56	-	-	ADJ
dti-1367	18	57	b	b	ADJ
dti-1367	18	58	cells	cell	NOUN
dti-1367	18	59	,	,	PUNCT
dti-1367	18	60	mature	mature	ADJ
dti-1367	18	61	,	,	PUNCT
dti-1367	18	62	and	and	CCONJ
dti-1367	18	63	memory	memory	NOUN
dti-1367	18	64	b	b	PROPN
dti-1367	18	65	cells	cell	NOUN
dti-1367	18	66	,	,	PUNCT
dti-1367	18	67	but	but	CCONJ
dti-1367	18	68	not	not	PART
dti-1367	18	69	on	on	ADP
dti-1367	18	70	lymphoid	lymphoid	ADJ
dti-1367	18	71	stem	stem	NOUN
dti-1367	18	72	cells	cell	NOUN
dti-1367	18	73	and	and	CCONJ
dti-1367	18	74	plasma	plasma	NOUN
dti-1367	18	75	cells	cell	NOUN
dti-1367	18	76	.	.	PUNCT
dti-1367	19	1	on	on	ADP
dti-1367	19	2	the	the	DET
dti-1367	19	3	basis	basis	NOUN
dti-1367	19	4	of	of	ADP
dti-1367	19	5	indirect	indirect	ADJ
dti-1367	19	6	evidence	evidence	NOUN
dti-1367	19	7	,	,	PUNCT
dti-1367	19	8	elimination	elimination	NOUN
dti-1367	19	9	of	of	ADP
dti-1367	19	10	the	the	DET
dti-1367	19	11	antigen	antigen	NOUN
dti-1367	19	12	-	-	PUNCT
dti-1367	19	13	presenting	present	VERB
dti-1367	19	14	capabilities	capability	NOUN
dti-1367	19	15	and	and	CCONJ
dti-1367	19	16	antigen	antigen	ADJ
dti-1367	19	17	nonspecific	nonspecific	ADJ
dti-1367	19	18	immune	immune	ADJ
dti-1367	19	19	functions	function	NOUN
dti-1367	19	20	of	of	ADP
dti-1367	19	21	b	b	NOUN
dti-1367	19	22	cells	cell	NOUN
dti-1367	19	23	appear	appear	VERB
dti-1367	19	24	to	to	PART
dti-1367	19	25	be	be	AUX
dti-1367	19	26	central	central	ADJ
dti-1367	19	27	to	to	ADP
dti-1367	19	28	the	the	DET
dti-1367	19	29	therapeutic	therapeutic	ADJ
dti-1367	19	30	efficacy	efficacy	NOUN
dti-1367	19	31	of	of	ADP
dti-1367	19	32	anti	anti	ADJ
dti-1367	19	33	-	-	PROPN
dti-1367	19	34	cd20	cd20	ADJ
dti-1367	19	35	b	b	NOUN
dti-1367	19	36	-	-	PUNCT
dti-1367	19	37	cell	cell	NOUN
dti-1367	19	38	therapies	therapy	NOUN
dti-1367	19	39	.	.	PUNCT
dti-1367	20	1	an	an	DET
dti-1367	20	2	important	important	ADJ
dti-1367	20	3	question	question	NOUN
dti-1367	20	4	is	be	AUX
dti-1367	20	5	this	this	PRON
dti-1367	20	6	—	—	PUNCT
dti-1367	20	7	why	why	SCONJ
dti-1367	20	8	does	do	AUX
dti-1367	20	9	the	the	DET
dti-1367	20	10	drug	drug	NOUN
dti-1367	20	11	need	need	VERB
dti-1367	20	12	to	to	PART
dti-1367	20	13	be	be	AUX
dti-1367	20	14	dosed	dose	VERB
dti-1367	20	15	at	at	ADP
dti-1367	20	16	fixed	fix	VERB
dti-1367	20	17	intervals	interval	NOUN
dti-1367	20	18	and	and	CCONJ
dti-1367	20	19	not	not	PART
dti-1367	20	20	based	base	VERB
dti-1367	20	21	on	on	ADP
dti-1367	20	22	a	a	DET
dti-1367	20	23	measurable	measurable	ADJ
dti-1367	20	24	endpoint	endpoint	NOUN
dti-1367	20	25	,	,	PUNCT
dti-1367	20	26	such	such	ADJ
dti-1367	20	27	as	as	ADP
dti-1367	20	28	tracking	track	VERB
dti-1367	20	29	peripheral	peripheral	ADJ
dti-1367	20	30	cd20	cd20	PROPN
dti-1367	20	31	cell	cell	NOUN
dti-1367	20	32	counts	count	VERB
dti-1367	20	33	?	?	PUNCT
dti-1367	21	1	there	there	PRON
dti-1367	21	2	is	be	VERB
dti-1367	21	3	minimal	minimal	ADJ
dti-1367	21	4	scientific	scientific	ADJ
dti-1367	21	5	validity	validity	NOUN
dti-1367	21	6	in	in	ADP
dti-1367	21	7	infusing	infuse	VERB
dti-1367	21	8	the	the	DET
dti-1367	21	9	drug	drug	NOUN
dti-1367	21	10	every	every	DET
dti-1367	21	11	6	6	NUM
dti-1367	21	12	months	month	NOUN
dti-1367	21	13	particularly	particularly	ADV
dti-1367	21	14	if	if	SCONJ
dti-1367	21	15	cd20	cd20	PROPN
dti-1367	21	16	cell	cell	NOUN
dti-1367	21	17	counts	count	NOUN
dti-1367	21	18	are	be	AUX
dti-1367	21	19	negligible	negligible	ADJ
dti-1367	21	20	in	in	ADP
dti-1367	21	21	the	the	DET
dti-1367	21	22	peripheral	peripheral	ADJ
dti-1367	21	23	blood	blood	NOUN
dti-1367	21	24	.	.	PUNCT
dti-1367	22	1	in	in	ADP
dti-1367	22	2	this	this	DET
dti-1367	22	3	analysis	analysis	NOUN
dti-1367	22	4	,	,	PUNCT
dti-1367	22	5	a	a	DET
dti-1367	22	6	case	case	NOUN
dti-1367	22	7	is	be	AUX
dti-1367	22	8	made	make	VERB
dti-1367	22	9	for	for	ADP
dti-1367	22	10	following	follow	VERB
dti-1367	22	11	cd19	cd19	PROPN
dti-1367	22	12	cell	cell	NOUN
dti-1367	22	13	populations	population	NOUN
dti-1367	22	14	as	as	ADP
dti-1367	22	15	a	a	DET
dti-1367	22	16	surrogate	surrogate	NOUN
dti-1367	22	17	for	for	ADP
dti-1367	22	18	cd20	cd20	PROPN
dti-1367	22	19	cells	cell	NOUN
dti-1367	22	20	on	on	ADP
dti-1367	22	21	a	a	DET
dti-1367	22	22	monthly	monthly	ADJ
dti-1367	22	23	basis	basis	NOUN
dti-1367	22	24	to	to	PART
dti-1367	22	25	guide	guide	VERB
dti-1367	22	26	ocr	ocr	ADJ
dti-1367	22	27	redosing	redose	VERB
dti-1367	22	28	parameters	parameter	NOUN
dti-1367	22	29	and	and	CCONJ
dti-1367	22	30	does	do	AUX
dti-1367	22	31	not	not	PART
dti-1367	22	32	follow	follow	VERB
dti-1367	22	33	a	a	DET
dti-1367	22	34	scheduled	scheduled	ADJ
dti-1367	22	35	dosing	dose	VERB
dti-1367	22	36	parameter	parameter	NOUN
dti-1367	22	37	.	.	PUNCT
dti-1367	23	1	keywords	keyword	NOUN
dti-1367	23	2	:	:	PUNCT
dti-1367	23	3	ocrelizumab	ocrelizumab	NOUN
dti-1367	23	4	,	,	PUNCT
dti-1367	23	5	multiple	multiple	ADJ
dti-1367	23	6	sclerosis	sclerosis	NOUN
dti-1367	23	7	,	,	PUNCT
dti-1367	23	8	cd19/20	cd19/20	NOUN
dti-1367	23	9	cells	cell	NOUN
dti-1367	23	10	,	,	PUNCT
dti-1367	23	11	anti	anti	ADJ
dti-1367	23	12	-	-	ADJ
dti-1367	23	13	cd	cd	ADJ
dti-1367	23	14	therapies	therapy	NOUN
dti-1367	23	15	,	,	PUNCT
dti-1367	23	16	rituxan	rituxan	NOUN
dti-1367	23	17	,	,	PUNCT
dti-1367	23	18	dosing	dose	VERB
dti-1367	23	19	schedules	schedule	NOUN
dti-1367	23	20	,	,	PUNCT
dti-1367	23	21	ocrevus	ocrevus	PROPN
dti-1367	23	22	,	,	PUNCT
dti-1367	23	23	neuromyelitis	neuromyelitis	PROPN
dti-1367	23	24	optica	optica	PROPN
dti-1367	23	25	spectrum	spectrum	NOUN
dti-1367	23	26	disorder	disorder	NOUN
dti-1367	23	27	received	receive	VERB
dti-1367	23	28	:	:	PUNCT
dti-1367	23	29	june	june	PROPN
dti-1367	23	30	30	30	NUM
dti-1367	23	31	,	,	PUNCT
dti-1367	23	32	2017	2017	NUM
dti-1367	23	33	.	.	PUNCT
dti-1367	24	1	accepted	accept	VERB
dti-1367	24	2	:	:	PUNCT
dti-1367	24	3	september	september	PROPN
dti-1367	24	4	4	4	NUM
dti-1367	24	5	,	,	PUNCT
dti-1367	24	6	2017	2017	NUM
dti-1367	24	7	.	.	PUNCT
dti-1367	25	1	peer	peer	NOUN
dti-1367	25	2	review	review	NOUN
dti-1367	25	3	:	:	PUNCT
dti-1367	25	4	two	two	NUM
dti-1367	25	5	peer	peer	NOUN
dti-1367	25	6	reviewers	reviewer	NOUN
dti-1367	25	7	contributed	contribute	VERB
dti-1367	25	8	to	to	ADP
dti-1367	25	9	the	the	DET
dti-1367	25	10	peer	peer	NOUN
dti-1367	25	11	review	review	NOUN
dti-1367	25	12	report	report	NOUN
dti-1367	25	13	.	.	PUNCT
dti-1367	26	1	reviewers	reviewer	NOUN
dti-1367	26	2	’	'	PUNCT
dti-1367	26	3	reports	report	NOUN
dti-1367	26	4	totaled	total	VERB
dti-1367	26	5	230	230	NUM
dti-1367	26	6	words	word	NOUN
dti-1367	26	7	,	,	PUNCT
dti-1367	26	8	excluding	exclude	VERB
dti-1367	26	9	any	any	DET
dti-1367	26	10	confidential	confidential	ADJ
dti-1367	26	11	comments	comment	NOUN
dti-1367	26	12	to	to	ADP
dti-1367	26	13	the	the	DET
dti-1367	26	14	academic	academic	ADJ
dti-1367	26	15	editor	editor	NOUN
dti-1367	26	16	.	.	PUNCT
dti-1367	27	1	type	type	NOUN
dti-1367	27	2	:	:	PUNCT
dti-1367	27	3	rapid	rapid	ADJ
dti-1367	27	4	communication	communication	NOUN
dti-1367	27	5	funding	funding	NOUN
dti-1367	27	6	:	:	PUNCT
dti-1367	27	7	the	the	DET
dti-1367	27	8	author(s	author(s	PROPN
dti-1367	27	9	)	)	PUNCT
dti-1367	27	10	received	receive	VERB
dti-1367	27	11	no	no	DET
dti-1367	27	12	financial	financial	ADJ
dti-1367	27	13	support	support	NOUN
dti-1367	27	14	for	for	ADP
dti-1367	27	15	the	the	DET
dti-1367	27	16	research	research	NOUN
dti-1367	27	17	,	,	PUNCT
dti-1367	27	18	authorship	authorship	NOUN
dti-1367	27	19	,	,	PUNCT
dti-1367	27	20	and/or	and/or	CCONJ
dti-1367	27	21	publication	publication	NOUN
dti-1367	27	22	of	of	ADP
dti-1367	27	23	this	this	DET
dti-1367	27	24	article	article	NOUN
dti-1367	27	25	.	.	PUNCT
dti-1367	28	1	declaration	declaration	NOUN
dti-1367	28	2	of	of	ADP
dti-1367	28	3	conflicting	conflicting	ADJ
dti-1367	28	4	interests	interest	NOUN
dti-1367	28	5	:	:	PUNCT
dti-1367	28	6	the	the	DET
dti-1367	28	7	author(s	author(s	NOUN
dti-1367	28	8	)	)	PUNCT
dti-1367	28	9	declared	declare	VERB
dti-1367	28	10	no	no	DET
dti-1367	28	11	potential	potential	ADJ
dti-1367	28	12	conflicts	conflict	NOUN
dti-1367	28	13	of	of	ADP
dti-1367	28	14	interest	interest	NOUN
dti-1367	28	15	with	with	ADP
dti-1367	28	16	respect	respect	NOUN
dti-1367	28	17	to	to	ADP
dti-1367	28	18	the	the	DET
dti-1367	28	19	research	research	NOUN
dti-1367	28	20	,	,	PUNCT
dti-1367	28	21	authorship	authorship	NOUN
dti-1367	28	22	,	,	PUNCT
dti-1367	28	23	and/or	and/or	CCONJ
dti-1367	28	24	publication	publication	NOUN
dti-1367	28	25	of	of	ADP
dti-1367	28	26	this	this	DET
dti-1367	28	27	article	article	NOUN
dti-1367	28	28	.	.	PUNCT
dti-1367	29	1	corresponding	correspond	VERB
dti-1367	29	2	author	author	NOUN
dti-1367	29	3	:	:	PUNCT
dti-1367	29	4	jagannadha	jagannadha	PROPN
dti-1367	29	5	avasarala	avasarala	PROPN
dti-1367	29	6	,	,	PUNCT
dti-1367	29	7	umg	umg	NOUN
dti-1367	29	8	-	-	PUNCT
dti-1367	29	9	neuroscience	neuroscience	NOUN
dti-1367	29	10	associates	associate	NOUN
dti-1367	29	11	,	,	PUNCT
dti-1367	29	12	greenville	greenville	PROPN
dti-1367	29	13	,	,	PUNCT
dti-1367	29	14	sc	sc	PROPN
dti-1367	29	15	29615	29615	NUM
dti-1367	29	16	,	,	PUNCT
dti-1367	29	17	usa	usa	PROPN
dti-1367	29	18	.	.	PROPN
dti-1367	29	19	email	email	NOUN
dti-1367	29	20	:	:	PUNCT
dti-1367	29	21	javasarala@ghs.org	javasarala@ghs.org	ADJ
dti-1367	29	22	737515	737515	NUM
dti-1367	29	23	dti0010.1177/1177392817737515drug	dti0010.1177/1177392817737515drug	PROPN
dti-1367	29	24	target	target	NOUN
dti-1367	29	25	insightsavasarala	insightsavasarala	NOUN
dti-1367	29	26	research	research	NOUN
dti-1367	29	27	-	-	PUNCT
dti-1367	29	28	article2017	article2017	PROPN
dti-1367	29	29	https://uk.sagepub.com/en-gb/journals-permissions	https://uk.sagepub.com/en-gb/journals-permission	NOUN
dti-1367	29	30	mailto:javasarala@ghs.org	mailto:javasarala@ghs.org	ADJ
dti-1367	29	31	2	2	NUM
dti-1367	29	32	drug	drug	NOUN
dti-1367	29	33	target	target	NOUN
dti-1367	29	34	insights	insight	NOUN
dti-1367	29	35	in	in	ADP
dti-1367	29	36	a	a	DET
dti-1367	29	37	study	study	NOUN
dti-1367	29	38	involving	involve	VERB
dti-1367	29	39	107	107	NUM
dti-1367	29	40	patients	patient	NOUN
dti-1367	29	41	with	with	ADP
dti-1367	29	42	ms	ms	PROPN
dti-1367	29	43	,	,	PUNCT
dti-1367	29	44	105	105	NUM
dti-1367	29	45	(	(	PUNCT
dti-1367	29	46	98.1	98.1	NUM
dti-1367	29	47	%	%	NOUN
dti-1367	29	48	)	)	PUNCT
dti-1367	29	49	had	have	VERB
dti-1367	29	50	at	at	ADV
dti-1367	29	51	least	least	ADJ
dti-1367	29	52	1	1	NUM
dti-1367	29	53	follow	follow	NOUN
dti-1367	29	54	-	-	PUNCT
dti-1367	29	55	up	up	NOUN
dti-1367	29	56	cd20	cd20	PROPN
dti-1367	29	57	count	count	NOUN
dti-1367	29	58	after	after	SCONJ
dti-1367	29	59	the	the	DET
dti-1367	29	60	first	first	ADJ
dti-1367	29	61	rtx	rtx	PROPN
dti-1367	29	62	administration	administration	NOUN
dti-1367	29	63	and	and	CCONJ
dti-1367	29	64	follow	follow	VERB
dti-1367	29	65	-	-	PUNCT
dti-1367	29	66	up	up	ADP
dti-1367	29	67	levels	level	NOUN
dti-1367	29	68	occurred	occur	VERB
dti-1367	29	69	at	at	ADP
dti-1367	29	70	an	an	DET
dti-1367	29	71	average	average	NOUN
dti-1367	29	72	of	of	ADP
dti-1367	29	73	138.3	138.3	NUM
dti-1367	29	74	±	±	NUM
dti-1367	29	75	121.4	121.4	NUM
dti-1367	29	76	days	day	NOUN
dti-1367	29	77	apart.8	apart.8	PROPN
dti-1367	29	78	the	the	DET
dti-1367	29	79	cd20	cd20	PROPN
dti-1367	29	80	counts	count	NOUN
dti-1367	29	81	of	of	ADP
dti-1367	29	82	patients	patient	NOUN
dti-1367	29	83	who	who	PRON
dti-1367	29	84	received	receive	VERB
dti-1367	29	85	1000	1000	NUM
dti-1367	29	86	mg	mg	NOUN
dti-1367	29	87	with	with	ADP
dti-1367	29	88	a	a	DET
dti-1367	29	89	concurrent	concurrent	ADJ
dti-1367	29	90	1000	1000	NUM
dti-1367	29	91	mg	mg	NOUN
dti-1367	29	92	dose	dose	VERB
dti-1367	29	93	2	2	NUM
dti-1367	29	94	weeks	week	NOUN
dti-1367	29	95	later	later	ADV
dti-1367	29	96	were	be	AUX
dti-1367	29	97	above	above	ADP
dti-1367	29	98	0	0	NUM
dti-1367	29	99	by	by	ADP
dti-1367	29	100	6	6	NUM
dti-1367	29	101	months	month	NOUN
dti-1367	29	102	in	in	ADP
dti-1367	29	103	20	20	NUM
dti-1367	29	104	%	%	NOUN
dti-1367	29	105	of	of	ADP
dti-1367	29	106	patients	patient	NOUN
dti-1367	29	107	,	,	PUNCT
dti-1367	29	108	whereas	whereas	SCONJ
dti-1367	29	109	3	3	NUM
dti-1367	29	110	%	%	NOUN
dti-1367	29	111	of	of	ADP
dti-1367	29	112	patients	patient	NOUN
dti-1367	29	113	had	have	VERB
dti-1367	29	114	a	a	DET
dti-1367	29	115	cd20	cd20	PROPN
dti-1367	29	116	count	count	NOUN
dti-1367	29	117	above	above	ADP
dti-1367	29	118	2	2	NUM
dti-1367	29	119	%	%	NOUN
dti-1367	29	120	of	of	ADP
dti-1367	29	121	baseline	baseline	NOUN
dti-1367	29	122	numbers	number	NOUN
dti-1367	29	123	.	.	PUNCT
dti-1367	30	1	of	of	ADP
dti-1367	30	2	patients	patient	NOUN
dti-1367	30	3	receiving	receive	VERB
dti-1367	30	4	a	a	DET
dti-1367	30	5	single	single	ADJ
dti-1367	30	6	rtx	rtx	NOUN
dti-1367	30	7	1000	1000	NUM
dti-1367	30	8	mg	mg	PROPN
dti-1367	30	9	dose	dose	PROPN
dti-1367	30	10	,	,	PUNCT
dti-1367	30	11	20	20	NUM
dti-1367	30	12	%	%	NOUN
dti-1367	30	13	had	have	VERB
dti-1367	30	14	a	a	DET
dti-1367	30	15	cd20	cd20	PROPN
dti-1367	30	16	count	count	NOUN
dti-1367	30	17	above	above	ADP
dti-1367	30	18	0	0	NUM
dti-1367	30	19	by	by	ADP
dti-1367	30	20	6	6	NUM
dti-1367	30	21	months	month	NOUN
dti-1367	30	22	,	,	PUNCT
dti-1367	30	23	and	and	CCONJ
dti-1367	30	24	5	5	NUM
dti-1367	30	25	%	%	NOUN
dti-1367	30	26	of	of	ADP
dti-1367	30	27	patients	patient	NOUN
dti-1367	30	28	had	have	VERB
dti-1367	30	29	>	>	X
dti-1367	30	30	2	2	NUM
dti-1367	30	31	%	%	NOUN
dti-1367	30	32	by	by	ADP
dti-1367	30	33	6	6	NUM
dti-1367	30	34	months	month	NOUN
dti-1367	30	35	.	.	PUNCT
dti-1367	31	1	this	this	DET
dti-1367	31	2	small	small	ADJ
dti-1367	31	3	,	,	PUNCT
dti-1367	31	4	observational	observational	ADJ
dti-1367	31	5	study	study	NOUN
dti-1367	31	6	in	in	ADP
dti-1367	31	7	one	one	NUM
dti-1367	31	8	ms	ms	PROPN
dti-1367	31	9	care	care	NOUN
dti-1367	31	10	clinic	clinic	PROPN
dti-1367	31	11	clearly	clearly	ADV
dti-1367	31	12	showed	show	VERB
dti-1367	31	13	how	how	SCONJ
dti-1367	31	14	widely	widely	ADV
dti-1367	31	15	different	different	ADJ
dti-1367	31	16	the	the	DET
dti-1367	31	17	repopulation	repopulation	NOUN
dti-1367	31	18	of	of	ADP
dti-1367	31	19	cd20	cd20	PROPN
dti-1367	31	20	counts	count	NOUN
dti-1367	31	21	were	be	AUX
dti-1367	31	22	,	,	PUNCT
dti-1367	31	23	suggesting	suggest	VERB
dti-1367	31	24	that	that	SCONJ
dti-1367	31	25	a	a	DET
dti-1367	31	26	fixed	fix	VERB
dti-1367	31	27	time	time	NOUN
dti-1367	31	28	scheduling	scheduling	NOUN
dti-1367	31	29	is	be	AUX
dti-1367	31	30	perhaps	perhaps	ADV
dti-1367	31	31	not	not	PART
dti-1367	31	32	optimal	optimal	ADJ
dti-1367	31	33	.	.	PUNCT
dti-1367	32	1	given	give	VERB
dti-1367	32	2	the	the	DET
dti-1367	32	3	wide	wide	ADJ
dti-1367	32	4	spectrum	spectrum	NOUN
dti-1367	32	5	of	of	ADP
dti-1367	32	6	unpredictable	unpredictable	ADJ
dti-1367	32	7	b	b	NOUN
dti-1367	32	8	-	-	PUNCT
dti-1367	32	9	cell	cell	NOUN
dti-1367	32	10	suppression	suppression	NOUN
dti-1367	32	11	,	,	PUNCT
dti-1367	32	12	it	it	PRON
dti-1367	32	13	is	be	AUX
dti-1367	32	14	impossible	impossible	ADJ
dti-1367	32	15	to	to	PART
dti-1367	32	16	predict	predict	VERB
dti-1367	32	17	how	how	SCONJ
dti-1367	32	18	each	each	DET
dti-1367	32	19	individual	individual	ADJ
dti-1367	32	20	patient	patient	NOUN
dti-1367	32	21	would	would	AUX
dti-1367	32	22	respond	respond	VERB
dti-1367	32	23	to	to	ADP
dti-1367	32	24	rtx	rtx	PROPN
dti-1367	32	25	and	and	CCONJ
dti-1367	32	26	what	what	PRON
dti-1367	32	27	the	the	DET
dti-1367	32	28	optimal	optimal	ADJ
dti-1367	32	29	dosing	dosing	NOUN
dti-1367	32	30	interval	interval	NOUN
dti-1367	32	31	ought	ought	AUX
dti-1367	32	32	to	to	PART
dti-1367	32	33	be	be	AUX
dti-1367	32	34	in	in	ADP
dti-1367	32	35	each	each	DET
dti-1367	32	36	patient	patient	NOUN
dti-1367	32	37	.	.	PUNCT
dti-1367	33	1	a	a	DET
dti-1367	33	2	more	more	ADV
dti-1367	33	3	obvious	obvious	ADJ
dti-1367	33	4	question	question	NOUN
dti-1367	33	5	is	be	AUX
dti-1367	33	6	whether	whether	SCONJ
dti-1367	33	7	scheduled	schedule	VERB
dti-1367	33	8	rtx	rtx	NOUN
dti-1367	33	9	infusions	infusion	NOUN
dti-1367	33	10	are	be	AUX
dti-1367	33	11	required	require	VERB
dti-1367	33	12	when	when	SCONJ
dti-1367	33	13	cd20	cd20	PROPN
dti-1367	33	14	counts	count	NOUN
dti-1367	33	15	are	be	AUX
dti-1367	33	16	negligible	negligible	ADJ
dti-1367	33	17	—	—	PUNCT
dti-1367	33	18	what	what	PRON
dti-1367	33	19	is	be	AUX
dti-1367	33	20	the	the	DET
dti-1367	33	21	target	target	NOUN
dti-1367	33	22	cell	cell	NOUN
dti-1367	33	23	when	when	SCONJ
dti-1367	33	24	counts	count	NOUN
dti-1367	33	25	are	be	AUX
dti-1367	33	26	less	less	ADJ
dti-1367	33	27	than	than	ADP
dti-1367	33	28	20	20	NUM
dti-1367	33	29	cells	cell	NOUN
dti-1367	33	30	/	/	SYM
dti-1367	33	31	μl	μl	NOUN
dti-1367	34	1	and	and	CCONJ
dti-1367	34	2	what	what	PRON
dti-1367	34	3	is	be	AUX
dti-1367	34	4	the	the	DET
dti-1367	34	5	rationale	rationale	NOUN
dti-1367	34	6	for	for	ADP
dti-1367	34	7	reinfusion	reinfusion	NOUN
dti-1367	34	8	?	?	PUNCT
dti-1367	35	1	there	there	PRON
dti-1367	35	2	are	be	VERB
dti-1367	35	3	no	no	DET
dti-1367	35	4	hard	hard	ADJ
dti-1367	35	5	data	datum	NOUN
dti-1367	35	6	to	to	PART
dti-1367	35	7	support	support	VERB
dti-1367	35	8	this	this	DET
dti-1367	35	9	treatment	treatment	NOUN
dti-1367	35	10	regimen	regiman	NOUN
dti-1367	35	11	.	.	PUNCT
dti-1367	36	1	in	in	ADP
dti-1367	36	2	another	another	DET
dti-1367	36	3	disease	disease	NOUN
dti-1367	36	4	model	model	NOUN
dti-1367	36	5	,	,	PUNCT
dti-1367	36	6	the	the	DET
dti-1367	36	7	treatment	treatment	NOUN
dti-1367	36	8	of	of	ADP
dti-1367	36	9	nmo	nmo	NOUN
dti-1367	36	10	/	/	SYM
dti-1367	36	11	nmosd	nmosd	NOUN
dti-1367	36	12	with	with	ADP
dti-1367	36	13	rtx	rtx	PROPN
dti-1367	36	14	tightly	tightly	ADV
dti-1367	36	15	scheduled	schedule	VERB
dti-1367	36	16	every	every	DET
dti-1367	36	17	6	6	NUM
dti-1367	36	18	to	to	PART
dti-1367	36	19	9	9	NUM
dti-1367	36	20	months	month	NOUN
dti-1367	36	21	to	to	PART
dti-1367	36	22	prevent	prevent	VERB
dti-1367	36	23	relapses	relapse	NOUN
dti-1367	36	24	was	be	AUX
dti-1367	36	25	not	not	PART
dti-1367	36	26	globally	globally	ADV
dti-1367	36	27	successful	successful	ADJ
dti-1367	36	28	either9–11	either9–11	VERB
dti-1367	36	29	casting	cast	VERB
dti-1367	36	30	doubt	doubt	NOUN
dti-1367	36	31	on	on	ADP
dti-1367	36	32	the	the	DET
dti-1367	36	33	theory	theory	NOUN
dti-1367	36	34	that	that	SCONJ
dti-1367	36	35	treatment	treatment	NOUN
dti-1367	36	36	protocols	protocol	NOUN
dti-1367	36	37	should	should	AUX
dti-1367	36	38	follow	follow	VERB
dti-1367	36	39	a	a	DET
dti-1367	36	40	scheduled	scheduled	ADJ
dti-1367	36	41	dosing	dosing	NOUN
dti-1367	36	42	pattern	pattern	NOUN
dti-1367	36	43	.	.	PUNCT
dti-1367	37	1	in	in	ADP
dti-1367	37	2	addition	addition	NOUN
dti-1367	37	3	,	,	PUNCT
dti-1367	37	4	greenberg	greenberg	PROPN
dti-1367	37	5	and	and	CCONJ
dti-1367	37	6	colleagues9	colleagues9	PROPN
dti-1367	37	7	retrospectively	retrospectively	ADV
dti-1367	37	8	reviewed	review	VERB
dti-1367	37	9	rtx	rtx	PROPN
dti-1367	37	10	dosing	dose	VERB
dti-1367	37	11	in	in	ADP
dti-1367	37	12	an	an	DET
dti-1367	37	13	nmo	nmo	NOUN
dti-1367	37	14	clinical	clinical	ADJ
dti-1367	37	15	cohort	cohort	NOUN
dti-1367	37	16	and	and	CCONJ
dti-1367	37	17	concluded	conclude	VERB
dti-1367	37	18	that	that	SCONJ
dti-1367	37	19	patients	patient	NOUN
dti-1367	37	20	should	should	AUX
dti-1367	37	21	be	be	AUX
dti-1367	37	22	redosed	redose	VERB
dti-1367	37	23	prior	prior	ADV
dti-1367	37	24	to	to	ADP
dti-1367	37	25	evidence	evidence	NOUN
dti-1367	37	26	of	of	ADP
dti-1367	37	27	b	b	NOUN
dti-1367	37	28	-	-	PUNCT
dti-1367	37	29	cell	cell	NOUN
dti-1367	37	30	reconstitution	reconstitution	NOUN
dti-1367	37	31	by	by	ADP
dti-1367	37	32	cd20	cd20	PROPN
dti-1367	37	33	counts	count	NOUN
dti-1367	37	34	which	which	PRON
dti-1367	37	35	is	be	AUX
dti-1367	37	36	probably	probably	ADV
dti-1367	37	37	optimal	optimal	ADJ
dti-1367	37	38	and	and	CCONJ
dti-1367	37	39	individualized	individualized	ADJ
dti-1367	37	40	.	.	PUNCT
dti-1367	38	1	pellkofer	pellkofer	PROPN
dti-1367	38	2	and	and	CCONJ
dti-1367	38	3	colleagues	colleague	NOUN
dti-1367	38	4	also	also	ADV
dti-1367	38	5	reviewed	review	VERB
dti-1367	38	6	rtx	rtx	NOUN
dti-1367	38	7	experience	experience	NOUN
dti-1367	38	8	in	in	ADP
dti-1367	38	9	patients	patient	NOUN
dti-1367	38	10	with	with	ADP
dti-1367	38	11	nmo	nmo	PROPN
dti-1367	38	12	,	,	PUNCT
dti-1367	38	13	and	and	CCONJ
dti-1367	38	14	based	base	VERB
dti-1367	38	15	on	on	ADP
dti-1367	38	16	their	their	PRON
dti-1367	38	17	results	result	NOUN
dti-1367	38	18	concluded	conclude	VERB
dti-1367	38	19	that	that	SCONJ
dti-1367	38	20	a	a	DET
dti-1367	38	21	fixed	fix	VERB
dti-1367	38	22	dosing	dose	VERB
dti-1367	38	23	schedule	schedule	NOUN
dti-1367	38	24	every	every	DET
dti-1367	38	25	69	69	NUM
dti-1367	38	26	months	month	NOUN
dti-1367	38	27	was	be	AUX
dti-1367	38	28	advisable.11	advisable.11	ADJ
dti-1367	38	29	studies	study	NOUN
dti-1367	38	30	have	have	AUX
dti-1367	38	31	also	also	ADV
dti-1367	38	32	shown	show	VERB
dti-1367	38	33	that	that	SCONJ
dti-1367	38	34	drugs	drug	NOUN
dti-1367	38	35	such	such	ADJ
dti-1367	38	36	as	as	ADP
dti-1367	38	37	rtx	rtx	PROPN
dti-1367	38	38	also	also	ADV
dti-1367	38	39	deplete	deplete	VERB
dti-1367	38	40	anti	anti	ADJ
dti-1367	38	41	-	-	ADJ
dti-1367	38	42	cd20	cd20	ADJ
dti-1367	38	43	t	t	NOUN
dti-1367	38	44	cells	cell	NOUN
dti-1367	38	45	demonstrating	demonstrate	VERB
dti-1367	38	46	that	that	DET
dti-1367	38	47	peripheral	peripheral	ADJ
dti-1367	38	48	depletion	depletion	NOUN
dti-1367	38	49	of	of	ADP
dti-1367	38	50	all	all	DET
dti-1367	38	51	cd20	cd20	PROPN
dti-1367	38	52	cells	cell	NOUN
dti-1367	38	53	contributes	contribute	VERB
dti-1367	38	54	to	to	ADP
dti-1367	38	55	suppression	suppression	NOUN
dti-1367	38	56	of	of	ADP
dti-1367	38	57	disease.12	disease.12	NOUN
dti-1367	38	58	taken	take	VERB
dti-1367	38	59	together	together	ADV
dti-1367	38	60	,	,	PUNCT
dti-1367	38	61	studies	study	NOUN
dti-1367	38	62	in	in	ADP
dti-1367	38	63	ra	ra	PROPN
dti-1367	38	64	,	,	PUNCT
dti-1367	38	65	ms	ms	NOUN
dti-1367	38	66	,	,	PUNCT
dti-1367	38	67	and	and	CCONJ
dti-1367	38	68	nmosd	nmosd	NOUN
dti-1367	38	69	have	have	AUX
dti-1367	38	70	demonstrated	demonstrate	VERB
dti-1367	38	71	why	why	SCONJ
dti-1367	38	72	a	a	DET
dti-1367	38	73	fixed	fix	VERB
dti-1367	38	74	dosing	dose	VERB
dti-1367	38	75	schedule	schedule	NOUN
dti-1367	38	76	with	with	ADP
dti-1367	38	77	rtx	rtx	PROPN
dti-1367	38	78	may	may	AUX
dti-1367	38	79	not	not	PART
dti-1367	38	80	be	be	AUX
dti-1367	38	81	optimal	optimal	ADJ
dti-1367	38	82	.	.	PUNCT
dti-1367	39	1	in	in	ADP
dti-1367	39	2	the	the	DET
dti-1367	39	3	case	case	NOUN
dti-1367	39	4	of	of	ADP
dti-1367	39	5	rtx	rtx	PROPN
dti-1367	39	6	,	,	PUNCT
dti-1367	39	7	the	the	DET
dti-1367	39	8	package	package	NOUN
dti-1367	39	9	insert	insert	VERB
dti-1367	39	10	clearly	clearly	ADV
dti-1367	39	11	notes	note	VERB
dti-1367	39	12	that	that	SCONJ
dti-1367	39	13	redosing	redose	VERB
dti-1367	39	14	for	for	ADP
dti-1367	39	15	patients	patient	NOUN
dti-1367	39	16	with	with	ADP
dti-1367	39	17	ra	ra	PROPN
dti-1367	39	18	is	be	AUX
dti-1367	39	19	based	base	VERB
dti-1367	39	20	on	on	ADP
dti-1367	39	21	(	(	PUNCT
dti-1367	39	22	1	1	X
dti-1367	39	23	)	)	PUNCT
dti-1367	39	24	clinical	clinical	ADJ
dti-1367	39	25	evaluation	evaluation	NOUN
dti-1367	39	26	or	or	CCONJ
dti-1367	39	27	(	(	PUNCT
dti-1367	39	28	2	2	NUM
dti-1367	39	29	)	)	PUNCT
dti-1367	39	30	every	every	DET
dti-1367	39	31	24	24	NUM
dti-1367	39	32	weeks	week	NOUN
dti-1367	39	33	.	.	PUNCT
dti-1367	40	1	however	however	ADV
dti-1367	40	2	,	,	PUNCT
dti-1367	40	3	no	no	DET
dti-1367	40	4	such	such	ADJ
dti-1367	40	5	options	option	NOUN
dti-1367	40	6	exist	exist	VERB
dti-1367	40	7	for	for	ADP
dti-1367	40	8	the	the	DET
dti-1367	40	9	use	use	NOUN
dti-1367	40	10	of	of	ADP
dti-1367	40	11	ocr	ocr	NOUN
dti-1367	40	12	in	in	ADP
dti-1367	40	13	patients	patient	NOUN
dti-1367	40	14	with	with	ADP
dti-1367	40	15	ms	ms	NOUN
dti-1367	40	16	and	and	CCONJ
dti-1367	40	17	dosing	dosing	NOUN
dti-1367	40	18	schedules	schedule	NOUN
dti-1367	40	19	are	be	AUX
dti-1367	40	20	fixed	fix	VERB
dti-1367	40	21	.	.	PUNCT
dti-1367	41	1	discussion	discussion	NOUN
dti-1367	41	2	the	the	DET
dti-1367	41	3	scheduled	scheduled	ADJ
dti-1367	41	4	dosing	dosing	NOUN
dti-1367	41	5	of	of	ADP
dti-1367	41	6	ocr	ocr	NOUN
dti-1367	41	7	for	for	ADP
dti-1367	41	8	both	both	DET
dti-1367	41	9	forms	form	NOUN
dti-1367	41	10	of	of	ADP
dti-1367	41	11	ms	ms	NOUN
dti-1367	41	12	is	be	AUX
dti-1367	41	13	slated	slate	VERB
dti-1367	41	14	at	at	ADP
dti-1367	41	15	6	6	NUM
dti-1367	41	16	-	-	PUNCT
dti-1367	41	17	month	month	NOUN
dti-1367	41	18	intervals	interval	NOUN
dti-1367	41	19	.	.	PUNCT
dti-1367	42	1	because	because	SCONJ
dti-1367	42	2	ocr	ocr	ADJ
dti-1367	42	3	avidly	avidly	ADV
dti-1367	42	4	targets	target	VERB
dti-1367	42	5	cd20	cd20	PROPN
dti-1367	42	6	cell	cell	NOUN
dti-1367	42	7	populations	population	NOUN
dti-1367	42	8	and	and	CCONJ
dti-1367	42	9	depletes	deplete	VERB
dti-1367	42	10	them	they	PRON
dti-1367	42	11	and	and	CCONJ
dti-1367	42	12	as	as	SCONJ
dti-1367	42	13	their	their	PRON
dti-1367	42	14	numbers	number	NOUN
dti-1367	42	15	can	can	AUX
dti-1367	42	16	be	be	AUX
dti-1367	42	17	monitored	monitor	VERB
dti-1367	42	18	by	by	ADP
dti-1367	42	19	peripheral	peripheral	ADJ
dti-1367	42	20	blood	blood	NOUN
dti-1367	42	21	counts	count	NOUN
dti-1367	42	22	of	of	ADP
dti-1367	42	23	cd19	cd19	PROPN
dti-1367	42	24	cells	cell	NOUN
dti-1367	42	25	,	,	PUNCT
dti-1367	42	26	it	it	PRON
dti-1367	42	27	remains	remain	VERB
dti-1367	42	28	poorly	poorly	ADV
dti-1367	42	29	understood	understand	VERB
dti-1367	42	30	why	why	SCONJ
dti-1367	42	31	ocr	ocr	PROPN
dti-1367	42	32	needs	need	VERB
dti-1367	42	33	to	to	PART
dti-1367	42	34	be	be	AUX
dti-1367	42	35	reinfused	reinfuse	VERB
dti-1367	42	36	at	at	ADP
dti-1367	42	37	scheduled	schedule	VERB
dti-1367	42	38	intervals	interval	NOUN
dti-1367	42	39	regardless	regardless	ADV
dti-1367	42	40	of	of	ADP
dti-1367	42	41	cd20	cd20	PROPN
dti-1367	42	42	cell	cell	NOUN
dti-1367	42	43	counts	count	NOUN
dti-1367	42	44	.	.	PUNCT
dti-1367	43	1	in	in	ADP
dti-1367	43	2	addition	addition	NOUN
dti-1367	43	3	,	,	PUNCT
dti-1367	43	4	in	in	ADP
dti-1367	43	5	up	up	ADP
dti-1367	43	6	to	to	PART
dti-1367	43	7	1	1	NUM
dti-1367	43	8	%	%	NOUN
dti-1367	43	9	(	(	PUNCT
dti-1367	43	10	12/1311	12/1311	NUM
dti-1367	43	11	)	)	PUNCT
dti-1367	43	12	of	of	ADP
dti-1367	43	13	all	all	DET
dti-1367	43	14	patients	patient	NOUN
dti-1367	43	15	with	with	ADP
dti-1367	43	16	ms	ms	NOUN
dti-1367	43	17	in	in	ADP
dti-1367	43	18	clinical	clinical	ADJ
dti-1367	43	19	trials	trial	NOUN
dti-1367	43	20	,	,	PUNCT
dti-1367	43	21	relapsing	relapse	VERB
dti-1367	43	22	and	and	CCONJ
dti-1367	43	23	primary	primary	ADJ
dti-1367	43	24	-	-	PUNCT
dti-1367	43	25	progressive	progressive	ADJ
dti-1367	43	26	types	type	NOUN
dti-1367	43	27	,	,	PUNCT
dti-1367	43	28	antidrug	antidrug	NOUN
dti-1367	43	29	antibodies	antibodie	VERB
dti-1367	43	30	(	(	PUNCT
dti-1367	43	31	adas	adas	PROPN
dti-1367	43	32	)	)	PUNCT
dti-1367	43	33	,	,	PUNCT
dti-1367	43	34	and	and	CCONJ
dti-1367	43	35	particularly	particularly	ADV
dti-1367	43	36	neutralizing	neutralizing	ADJ
dti-1367	43	37	antibodies	antibody	NOUN
dti-1367	43	38	appeared	appear	VERB
dti-1367	43	39	in	in	ADP
dti-1367	43	40	2	2	NUM
dti-1367	43	41	patients	patient	NOUN
dti-1367	43	42	,	,	PUNCT
dti-1367	43	43	clearing	clear	VERB
dti-1367	43	44	ocr	ocr	NOUN
dti-1367	43	45	faster	fast	ADV
dti-1367	43	46	and	and	CCONJ
dti-1367	43	47	rendering	render	VERB
dti-1367	43	48	b	b	NOUN
dti-1367	43	49	-	-	PUNCT
dti-1367	43	50	cell	cell	NOUN
dti-1367	43	51	repletion	repletion	NOUN
dti-1367	43	52	quicker	quick	ADV
dti-1367	43	53	.	.	PUNCT
dti-1367	44	1	this	this	PRON
dti-1367	44	2	is	be	AUX
dti-1367	44	3	one	one	NUM
dti-1367	44	4	other	other	ADJ
dti-1367	44	5	reason	reason	NOUN
dti-1367	44	6	why	why	SCONJ
dti-1367	44	7	following	follow	VERB
dti-1367	44	8	cd20	cd20	PROPN
dti-1367	44	9	cells	cell	NOUN
dti-1367	44	10	are	be	AUX
dti-1367	44	11	prudent	prudent	ADJ
dti-1367	44	12	.	.	PUNCT
dti-1367	45	1	additional	additional	ADJ
dti-1367	45	2	validity	validity	NOUN
dti-1367	45	3	and	and	CCONJ
dti-1367	45	4	strength	strength	NOUN
dti-1367	45	5	of	of	ADP
dti-1367	45	6	my	my	PRON
dti-1367	45	7	analysis	analysis	NOUN
dti-1367	45	8	come	come	VERB
dti-1367	45	9	from	from	ADP
dti-1367	45	10	the	the	DET
dti-1367	45	11	original	original	ADJ
dti-1367	45	12	data	datum	NOUN
dti-1367	45	13	submitted	submit	VERB
dti-1367	45	14	to	to	ADP
dti-1367	45	15	the	the	DET
dti-1367	45	16	center	center	NOUN
dti-1367	45	17	for	for	ADP
dti-1367	45	18	drug	drug	NOUN
dti-1367	45	19	evaluation	evaluation	NOUN
dti-1367	45	20	and	and	CCONJ
dti-1367	45	21	research	research	NOUN
dti-1367	45	22	as	as	SCONJ
dti-1367	45	23	shown	show	VERB
dti-1367	45	24	in	in	ADP
dti-1367	45	25	figures	figure	NOUN
dti-1367	45	26	1	1	NUM
dti-1367	45	27	and	and	CCONJ
dti-1367	45	28	2	2	NUM
dti-1367	45	29	which	which	PRON
dti-1367	45	30	depict	depict	VERB
dti-1367	45	31	cd19	cd19	PROPN
dti-1367	45	32	cell	cell	NOUN
dti-1367	45	33	populations	population	NOUN
dti-1367	45	34	in	in	ADP
dti-1367	45	35	clinical	clinical	ADJ
dti-1367	45	36	trials	trial	NOUN
dti-1367	45	37	at	at	ADP
dti-1367	45	38	<	<	X
dti-1367	45	39	20	20	NUM
dti-1367	45	40	cells	cell	NOUN
dti-1367	45	41	/	/	SYM
dti-1367	45	42	μl	μl	CCONJ
dti-1367	45	43	,	,	PUNCT
dti-1367	45	44	the	the	DET
dti-1367	45	45	lower	low	ADJ
dti-1367	45	46	limit	limit	NOUN
dti-1367	45	47	of	of	ADP
dti-1367	45	48	quantification	quantification	NOUN
dti-1367	45	49	,	,	PUNCT
dti-1367	45	50	at	at	ADP
dti-1367	45	51	24	24	NUM
dti-1367	45	52	weeks	week	NOUN
dti-1367	45	53	postinfusion	postinfusion	NOUN
dti-1367	45	54	.	.	PUNCT
dti-1367	46	1	these	these	DET
dti-1367	46	2	results	result	NOUN
dti-1367	46	3	are	be	AUX
dti-1367	46	4	derived	derive	VERB
dti-1367	46	5	from	from	ADP
dti-1367	46	6	the	the	DET
dti-1367	46	7	clinical	clinical	ADJ
dti-1367	46	8	pharmacology	pharmacology	NOUN
dti-1367	46	9	and	and	CCONJ
dti-1367	46	10	biopharmaceutics	biopharmaceutics	NOUN
dti-1367	46	11	review	review	NOUN
dti-1367	46	12	(	(	PUNCT
dti-1367	46	13	application	application	NOUN
dti-1367	46	14	no	no	NOUN
dti-1367	46	15	.	.	PUNCT
dti-1367	47	1	761053orig1s000	761053orig1s000	NUM
dti-1367	47	2	)	)	PUNCT
dti-1367	47	3	,	,	PUNCT
dti-1367	48	1	the	the	DET
dti-1367	48	2	document	document	NOUN
dti-1367	48	3	that	that	PRON
dti-1367	48	4	was	be	AUX
dti-1367	48	5	originally	originally	ADV
dti-1367	48	6	submitted	submit	VERB
dti-1367	48	7	to	to	ADP
dti-1367	48	8	the	the	DET
dti-1367	48	9	fda	fda	PROPN
dti-1367	48	10	for	for	ADP
dti-1367	48	11	evaluation	evaluation	NOUN
dti-1367	48	12	and	and	CCONJ
dti-1367	48	13	approval	approval	NOUN
dti-1367	48	14	of	of	ADP
dti-1367	48	15	ocrevus	ocrevus	PROPN
dti-1367	48	16	.	.	PUNCT
dti-1367	49	1	finally	finally	ADV
dti-1367	49	2	,	,	PUNCT
dti-1367	49	3	in	in	ADP
dti-1367	49	4	the	the	DET
dti-1367	49	5	package	package	NOUN
dti-1367	49	6	insert	insert	NOUN
dti-1367	49	7	for	for	ADP
dti-1367	49	8	ocr	ocr	NOUN
dti-1367	49	9	,	,	PUNCT
dti-1367	49	10	one	one	NUM
dti-1367	49	11	of	of	ADP
dti-1367	49	12	the	the	DET
dti-1367	49	13	statements	statement	NOUN
dti-1367	49	14	warns	warn	VERB
dti-1367	49	15	not	not	PART
dti-1367	49	16	to	to	PART
dti-1367	49	17	administer	administer	VERB
dti-1367	49	18	subsequent	subsequent	ADJ
dti-1367	49	19	doses	dose	NOUN
dti-1367	49	20	if	if	SCONJ
dti-1367	49	21	the	the	DET
dti-1367	49	22	separation	separation	NOUN
dti-1367	49	23	between	between	ADP
dti-1367	49	24	doses	dose	NOUN
dti-1367	49	25	is	be	AUX
dti-1367	49	26	not	not	PART
dti-1367	49	27	at	at	ADV
dti-1367	49	28	least	least	ADV
dti-1367	49	29	5	5	NUM
dti-1367	49	30	months	month	NOUN
dti-1367	49	31	.	.	PUNCT
dti-1367	50	1	this	this	DET
dti-1367	50	2	statement	statement	NOUN
dti-1367	50	3	is	be	AUX
dti-1367	50	4	pithy	pithy	ADJ
dti-1367	50	5	but	but	CCONJ
dti-1367	50	6	ignores	ignore	VERB
dti-1367	50	7	the	the	DET
dti-1367	50	8	fact	fact	NOUN
dti-1367	50	9	that	that	SCONJ
dti-1367	50	10	repopulation	repopulation	NOUN
dti-1367	50	11	of	of	ADP
dti-1367	50	12	cd20	cd20	PROPN
dti-1367	50	13	cells	cell	NOUN
dti-1367	50	14	could	could	AUX
dti-1367	50	15	also	also	ADV
dti-1367	50	16	remain	remain	VERB
dti-1367	50	17	undetectable	undetectable	ADJ
dti-1367	50	18	at	at	ADP
dti-1367	50	19	6	6	NUM
dti-1367	50	20	months	month	NOUN
dti-1367	50	21	postinfusion	postinfusion	NOUN
dti-1367	50	22	.	.	PUNCT
dti-1367	51	1	hence	hence	ADV
dti-1367	51	2	,	,	PUNCT
dti-1367	51	3	to	to	PART
dti-1367	51	4	correctly	correctly	ADV
dti-1367	51	5	assess	assess	VERB
dti-1367	51	6	the	the	DET
dti-1367	51	7	need	need	NOUN
dti-1367	51	8	to	to	PART
dti-1367	51	9	reinfuse	reinfuse	VERB
dti-1367	51	10	,	,	PUNCT
dti-1367	51	11	following	follow	VERB
dti-1367	51	12	monthly	monthly	ADJ
dti-1367	51	13	cd19	cd19	PROPN
dti-1367	51	14	cell	cell	NOUN
dti-1367	51	15	counts	count	NOUN
dti-1367	51	16	is	be	AUX
dti-1367	51	17	a	a	DET
dti-1367	51	18	small	small	ADJ
dti-1367	51	19	price	price	NOUN
dti-1367	51	20	to	to	PART
dti-1367	51	21	pay	pay	VERB
dti-1367	51	22	both	both	PRON
dti-1367	51	23	in	in	ADP
dti-1367	51	24	the	the	DET
dti-1367	51	25	scientific	scientific	ADJ
dti-1367	51	26	and	and	CCONJ
dti-1367	51	27	literal	literal	ADJ
dti-1367	51	28	sense	sense	NOUN
dti-1367	51	29	.	.	PUNCT
dti-1367	52	1	in	in	ADP
dti-1367	52	2	addition	addition	NOUN
dti-1367	52	3	,	,	PUNCT
dti-1367	52	4	data	datum	NOUN
dti-1367	52	5	on	on	ADP
dti-1367	52	6	long	long	ADJ
dti-1367	52	7	-	-	PUNCT
dti-1367	52	8	term	term	NOUN
dti-1367	52	9	ocr	ocr	NOUN
dti-1367	52	10	therapy	therapy	NOUN
dti-1367	52	11	are	be	AUX
dti-1367	52	12	lacking	lack	VERB
dti-1367	52	13	and	and	CCONJ
dti-1367	52	14	concern	concern	NOUN
dti-1367	52	15	regarding	regard	VERB
dti-1367	52	16	prolonged	prolonged	ADJ
dti-1367	52	17	b	b	NOUN
dti-1367	52	18	-	-	PUNCT
dti-1367	52	19	cell	cell	NOUN
dti-1367	52	20	depletion	depletion	NOUN
dti-1367	52	21	remains	remain	VERB
dti-1367	52	22	;	;	PUNCT
dti-1367	52	23	these	these	PRON
dti-1367	52	24	could	could	AUX
dti-1367	52	25	come	come	VERB
dti-1367	52	26	to	to	ADP
dti-1367	52	27	light	light	NOUN
dti-1367	52	28	in	in	ADP
dti-1367	52	29	postmarketing	postmarkete	VERB
dti-1367	52	30	data	datum	NOUN
dti-1367	52	31	.	.	PUNCT
dti-1367	53	1	figure	figure	NOUN
dti-1367	53	2	1	1	NUM
dti-1367	53	3	.	.	PUNCT
dti-1367	54	1	median	median	ADJ
dti-1367	54	2	peripheral	peripheral	ADJ
dti-1367	54	3	blood	blood	NOUN
dti-1367	54	4	b	b	NOUN
dti-1367	54	5	-	-	PUNCT
dti-1367	54	6	cell	cell	NOUN
dti-1367	54	7	profiles	profile	NOUN
dti-1367	54	8	following	follow	VERB
dti-1367	54	9	intravenous	intravenous	ADJ
dti-1367	54	10	ocrelizumab	ocrelizumab	NOUN
dti-1367	54	11	(	(	PUNCT
dti-1367	54	12	ocr	ocr	PROPN
dti-1367	54	13	)	)	PUNCT
dti-1367	54	14	administration	administration	NOUN
dti-1367	54	15	in	in	ADP
dti-1367	54	16	subjects	subject	NOUN
dti-1367	54	17	with	with	ADP
dti-1367	54	18	rheumatoid	rheumatoid	NOUN
dti-1367	54	19	arthritis	arthritis	NOUN
dti-1367	54	20	in	in	ADP
dti-1367	54	21	study	study	PROPN
dti-1367	54	22	act2847	act2847	PROPN
dti-1367	54	23	g.	g.	PROPN
dti-1367	54	24	avasarala	avasarala	PROPN
dti-1367	54	25	3	3	NUM
dti-1367	54	26	specifically	specifically	ADV
dti-1367	54	27	,	,	PUNCT
dti-1367	54	28	ocr	ocr	PROPN
dti-1367	54	29	is	be	AUX
dti-1367	54	30	an	an	DET
dti-1367	54	31	expensive	expensive	ADJ
dti-1367	54	32	biologic	biologic	NOUN
dti-1367	54	33	that	that	PRON
dti-1367	54	34	promises	promise	VERB
dti-1367	54	35	to	to	PART
dti-1367	54	36	deliver	deliver	VERB
dti-1367	54	37	clinical	clinical	ADJ
dti-1367	54	38	benefit	benefit	NOUN
dti-1367	54	39	.	.	PUNCT
dti-1367	55	1	however	however	ADV
dti-1367	55	2	,	,	PUNCT
dti-1367	55	3	the	the	DET
dti-1367	55	4	long	long	ADJ
dti-1367	55	5	-	-	PUNCT
dti-1367	55	6	term	term	NOUN
dti-1367	55	7	safety	safety	NOUN
dti-1367	55	8	of	of	ADP
dti-1367	55	9	repeated	repeat	VERB
dti-1367	55	10	ocr	ocr	ADJ
dti-1367	55	11	treatment	treatment	NOUN
dti-1367	55	12	remains	remain	VERB
dti-1367	55	13	unknown	unknown	ADJ
dti-1367	55	14	and	and	CCONJ
dti-1367	55	15	there	there	PRON
dti-1367	55	16	is	be	VERB
dti-1367	55	17	no	no	DET
dti-1367	55	18	scientific	scientific	ADJ
dti-1367	55	19	validity	validity	NOUN
dti-1367	55	20	to	to	ADP
dti-1367	55	21	giving	give	VERB
dti-1367	55	22	the	the	DET
dti-1367	55	23	drug	drug	NOUN
dti-1367	55	24	when	when	SCONJ
dti-1367	55	25	cd20	cd20	PROPN
dti-1367	55	26	cells	cell	NOUN
dti-1367	55	27	are	be	AUX
dti-1367	55	28	nonexistent	nonexistent	ADJ
dti-1367	55	29	in	in	ADP
dti-1367	55	30	the	the	DET
dti-1367	55	31	periphery	periphery	NOUN
dti-1367	55	32	at	at	ADP
dti-1367	55	33	counts	count	NOUN
dti-1367	55	34	below	below	ADP
dti-1367	55	35	20	20	NUM
dti-1367	55	36	cells	cell	NOUN
dti-1367	55	37	/	/	SYM
dti-1367	55	38	μl	μl	NOUN
dti-1367	55	39	.	.	PUNCT
dti-1367	56	1	any	any	DET
dti-1367	56	2	effective	effective	ADJ
dti-1367	56	3	treatment	treatment	NOUN
dti-1367	56	4	strategy	strategy	NOUN
dti-1367	56	5	that	that	PRON
dti-1367	56	6	aims	aim	VERB
dti-1367	56	7	to	to	PART
dti-1367	56	8	minimize	minimize	VERB
dti-1367	56	9	unnecessary	unnecessary	ADJ
dti-1367	56	10	patient	patient	ADJ
dti-1367	56	11	exposure	exposure	NOUN
dti-1367	56	12	to	to	ADP
dti-1367	56	13	the	the	DET
dti-1367	56	14	drug	drug	NOUN
dti-1367	56	15	helps	help	VERB
dti-1367	56	16	with	with	ADP
dti-1367	56	17	patient	patient	ADJ
dti-1367	56	18	safety	safety	NOUN
dti-1367	56	19	and	and	CCONJ
dti-1367	56	20	allows	allow	VERB
dti-1367	56	21	for	for	ADP
dti-1367	56	22	significant	significant	ADJ
dti-1367	56	23	cost	cost	NOUN
dti-1367	56	24	savings	saving	NOUN
dti-1367	56	25	to	to	ADP
dti-1367	56	26	the	the	DET
dti-1367	56	27	patient	patient	NOUN
dti-1367	56	28	and	and	CCONJ
dti-1367	56	29	third	third	ADJ
dti-1367	56	30	-	-	PUNCT
dti-1367	56	31	party	party	NOUN
dti-1367	56	32	payers	payer	NOUN
dti-1367	56	33	.	.	PUNCT
dti-1367	57	1	therefore	therefore	ADV
dti-1367	57	2	,	,	PUNCT
dti-1367	57	3	the	the	DET
dti-1367	57	4	following	follow	VERB
dti-1367	57	5	recommendations	recommendation	NOUN
dti-1367	57	6	are	be	AUX
dti-1367	57	7	suggested	suggest	VERB
dti-1367	57	8	.	.	PUNCT
dti-1367	58	1	(	(	PUNCT
dti-1367	58	2	1	1	X
dti-1367	58	3	)	)	PUNCT
dti-1367	58	4	if	if	SCONJ
dti-1367	58	5	the	the	DET
dti-1367	58	6	disease	disease	NOUN
dti-1367	58	7	activity	activity	NOUN
dti-1367	58	8	stabilizes	stabilize	VERB
dti-1367	58	9	both	both	PRON
dti-1367	58	10	clinically	clinically	ADV
dti-1367	58	11	and	and	CCONJ
dti-1367	58	12	from	from	ADP
dti-1367	58	13	a	a	DET
dti-1367	58	14	radiological	radiological	ADJ
dti-1367	58	15	perspective	perspective	NOUN
dti-1367	58	16	,	,	PUNCT
dti-1367	58	17	less	less	ADV
dti-1367	58	18	frequent	frequent	ADJ
dti-1367	58	19	retreatment	retreatment	NOUN
dti-1367	58	20	might	might	AUX
dti-1367	58	21	be	be	AUX
dti-1367	58	22	sufficient	sufficient	ADJ
dti-1367	58	23	to	to	PART
dti-1367	58	24	prevent	prevent	VERB
dti-1367	58	25	relapses	relapse	NOUN
dti-1367	58	26	,	,	PUNCT
dti-1367	58	27	although	although	SCONJ
dti-1367	58	28	the	the	DET
dti-1367	58	29	correlation	correlation	NOUN
dti-1367	58	30	between	between	ADP
dti-1367	58	31	clinical	clinical	ADJ
dti-1367	58	32	/	/	SYM
dti-1367	58	33	radiological	radiological	ADJ
dti-1367	58	34	criteria	criterion	NOUN
dti-1367	58	35	to	to	PART
dti-1367	58	36	disease	disease	NOUN
dti-1367	58	37	activity	activity	NOUN
dti-1367	58	38	is	be	AUX
dti-1367	58	39	not	not	PART
dti-1367	58	40	a	a	DET
dti-1367	58	41	linear	linear	ADJ
dti-1367	58	42	relationship	relationship	NOUN
dti-1367	58	43	and	and	CCONJ
dti-1367	58	44	therefore	therefore	ADV
dti-1367	58	45	must	must	AUX
dti-1367	58	46	be	be	AUX
dti-1367	58	47	individualized	individualize	VERB
dti-1367	58	48	based	base	VERB
dti-1367	58	49	on	on	ADP
dti-1367	58	50	monthly	monthly	ADJ
dti-1367	58	51	cd20	cd20	PROPN
dti-1367	58	52	cell	cell	NOUN
dti-1367	58	53	counts	count	VERB
dti-1367	58	54	by	by	ADP
dti-1367	58	55	monitoring	monitor	VERB
dti-1367	58	56	cd19	cd19	PROPN
dti-1367	58	57	cells	cell	NOUN
dti-1367	58	58	.	.	PUNCT
dti-1367	59	1	(	(	PUNCT
dti-1367	59	2	2	2	X
dti-1367	59	3	)	)	PUNCT
dti-1367	59	4	alternatively	alternatively	ADV
dti-1367	59	5	,	,	PUNCT
dti-1367	59	6	cd20	cd20	PROPN
dti-1367	59	7	cell	cell	NOUN
dti-1367	59	8	counts	count	NOUN
dti-1367	59	9	must	must	AUX
dti-1367	59	10	be	be	AUX
dti-1367	59	11	monitored	monitor	VERB
dti-1367	59	12	monthly	monthly	ADV
dti-1367	59	13	on	on	ADP
dti-1367	59	14	a	a	DET
dti-1367	59	15	routine	routine	ADJ
dti-1367	59	16	basis	basis	NOUN
dti-1367	59	17	irrespective	irrespective	ADV
dti-1367	59	18	of	of	ADP
dti-1367	59	19	clinical	clinical	ADJ
dti-1367	59	20	or	or	CCONJ
dti-1367	59	21	radiological	radiological	ADJ
dti-1367	59	22	status	status	NOUN
dti-1367	59	23	and	and	CCONJ
dti-1367	59	24	reinfusion	reinfusion	NOUN
dti-1367	59	25	of	of	ADP
dti-1367	59	26	the	the	DET
dti-1367	59	27	drug	drug	NOUN
dti-1367	59	28	carried	carry	VERB
dti-1367	59	29	out	out	ADP
dti-1367	59	30	after	after	SCONJ
dti-1367	59	31	the	the	DET
dti-1367	59	32	cell	cell	NOUN
dti-1367	59	33	population	population	NOUN
dti-1367	59	34	rebounds	rebound	VERB
dti-1367	59	35	to	to	ADP
dti-1367	59	36	≥20	≥20	NOUN
dti-1367	59	37	cells	cell	NOUN
dti-1367	59	38	/	/	SYM
dti-1367	59	39	μl	μl	NUM
dti-1367	59	40	;	;	PUNCT
dti-1367	59	41	this	this	PRON
dti-1367	59	42	holds	hold	VERB
dti-1367	59	43	true	true	ADJ
dti-1367	59	44	also	also	ADV
dti-1367	59	45	for	for	ADP
dti-1367	59	46	patients	patient	NOUN
dti-1367	59	47	who	who	PRON
dti-1367	59	48	develop	develop	VERB
dti-1367	59	49	adas	adas	PROPN
dti-1367	59	50	that	that	PRON
dti-1367	59	51	can	can	AUX
dti-1367	59	52	neutralize	neutralize	VERB
dti-1367	59	53	ocr	ocr	PROPN
dti-1367	59	54	activityin	activityin	PROPN
dti-1367	59	55	which	which	DET
dti-1367	59	56	case	case	NOUN
dti-1367	59	57	the	the	DET
dti-1367	59	58	cd19	cd19	PROPN
dti-1367	59	59	cell	cell	NOUN
dti-1367	59	60	count	count	NOUN
dti-1367	59	61	would	would	AUX
dti-1367	59	62	repopulate	repopulate	VERB
dti-1367	59	63	.	.	PUNCT
dti-1367	60	1	author	author	NOUN
dti-1367	60	2	contributions	contribution	VERB
dti-1367	60	3	ja	ja	PROPN
dti-1367	60	4	:	:	PUNCT
dti-1367	60	5	idea	idea	NOUN
dti-1367	60	6	/	/	SYM
dti-1367	60	7	conceptualization	conceptualization	NOUN
dti-1367	60	8	,	,	PUNCT
dti-1367	60	9	data	datum	NOUN
dti-1367	60	10	collection	collection	NOUN
dti-1367	60	11	/	/	SYM
dti-1367	60	12	collation	collation	NOUN
dti-1367	60	13	and	and	CCONJ
dti-1367	60	14	analysis	analysis	NOUN
dti-1367	60	15	,	,	PUNCT
dti-1367	60	16	as	as	ADV
dti-1367	60	17	well	well	ADV
dti-1367	60	18	as	as	ADP
dti-1367	60	19	write	write	NOUN
dti-1367	60	20	-	-	PUNCT
dti-1367	60	21	up	up	NOUN
dti-1367	60	22	of	of	ADP
dti-1367	60	23	the	the	DET
dti-1367	60	24	manuscript	manuscript	NOUN
dti-1367	60	25	and	and	CCONJ
dti-1367	60	26	submission	submission	NOUN
dti-1367	60	27	.	.	PUNCT
dti-1367	61	1	references	reference	NOUN
dti-1367	61	2	1	1	NUM
dti-1367	61	3	.	.	PUNCT
dti-1367	61	4	browning	brown	VERB
dti-1367	61	5	jl	jl	PROPN
dti-1367	61	6	.	.	PUNCT
dti-1367	62	1	b	b	NOUN
dti-1367	62	2	cells	cell	NOUN
dti-1367	62	3	move	move	VERB
dti-1367	62	4	to	to	ADP
dti-1367	62	5	centre	centre	NOUN
dti-1367	62	6	stage	stage	NOUN
dti-1367	62	7	:	:	PUNCT
dti-1367	62	8	novel	novel	ADJ
dti-1367	62	9	opportunities	opportunity	NOUN
dti-1367	62	10	for	for	ADP
dti-1367	62	11	autoimmune	autoimmune	ADJ
dti-1367	62	12	disease	disease	NOUN
dti-1367	62	13	treatment	treatment	NOUN
dti-1367	62	14	.	.	PUNCT
dti-1367	63	1	nat	nat	PROPN
dti-1367	63	2	rev	rev	VERB
dti-1367	63	3	drug	drug	NOUN
dti-1367	63	4	discov	discov	NOUN
dti-1367	63	5	.	.	PUNCT
dti-1367	64	1	2006;5:564–576	2006;5:564–576	NUM
dti-1367	64	2	.	.	PUNCT
dti-1367	65	1	2	2	NUM
dti-1367	65	2	.	.	NUM
dti-1367	65	3	edwards	edwards	PROPN
dti-1367	65	4	jc	jc	PROPN
dti-1367	65	5	,	,	PUNCT
dti-1367	65	6	cambridge	cambridge	PROPN
dti-1367	65	7	g.	g.	PROPN
dti-1367	65	8	prospects	prospect	NOUN
dti-1367	65	9	for	for	ADP
dti-1367	65	10	b	b	NOUN
dti-1367	65	11	-	-	PUNCT
dti-1367	65	12	cell	cell	NOUN
dti-1367	65	13	-	-	PUNCT
dti-1367	65	14	targeted	target	VERB
dti-1367	65	15	therapy	therapy	NOUN
dti-1367	65	16	in	in	ADP
dti-1367	65	17	autoimmune	autoimmune	ADJ
dti-1367	65	18	disease	disease	NOUN
dti-1367	65	19	.	.	PUNCT
dti-1367	66	1	rheumatol	rheumatol	NOUN
dti-1367	66	2	.	.	PUNCT
dti-1367	67	1	(	(	PUNCT
dti-1367	67	2	oxford	oxford	PROPN
dti-1367	67	3	)	)	PUNCT
dti-1367	67	4	.	.	PUNCT
dti-1367	68	1	2005;44:151–156	2005;44:151–156	NUM
dti-1367	68	2	.	.	PUNCT
dti-1367	69	1	3	3	X
dti-1367	69	2	.	.	X
dti-1367	69	3	hoyer	hoyer	PROPN
dti-1367	69	4	bf	bf	PROPN
dti-1367	69	5	,	,	PUNCT
dti-1367	69	6	manz	manz	PROPN
dti-1367	69	7	ra	ra	PROPN
dti-1367	69	8	,	,	PUNCT
dti-1367	69	9	radbruch	radbruch	VERB
dti-1367	69	10	a	a	DET
dti-1367	69	11	,	,	PUNCT
dti-1367	69	12	hiepe	hiepe	PROPN
dti-1367	69	13	f.	f.	PROPN
dti-1367	69	14	long	long	ADV
dti-1367	69	15	-	-	PUNCT
dti-1367	69	16	lived	live	VERB
dti-1367	69	17	plasma	plasma	NOUN
dti-1367	69	18	cells	cell	NOUN
dti-1367	69	19	and	and	CCONJ
dti-1367	69	20	their	their	PRON
dti-1367	69	21	contribution	contribution	NOUN
dti-1367	69	22	to	to	ADP
dti-1367	69	23	autoimmunity	autoimmunity	NOUN
dti-1367	69	24	.	.	PUNCT
dti-1367	70	1	ann	ann	PROPN
dti-1367	70	2	n	n	PROPN
dti-1367	70	3	y	y	PROPN
dti-1367	70	4	acad	acad	PROPN
dti-1367	70	5	sci	sci	PROPN
dti-1367	70	6	.	.	PROPN
dti-1367	70	7	2005;1050:124–133	2005;1050:124–133	NUM
dti-1367	70	8	.	.	PUNCT
dti-1367	71	1	4	4	NUM
dti-1367	71	2	.	.	X
dti-1367	71	3	beum	beum	NOUN
dti-1367	71	4	pv	pv	PROPN
dti-1367	71	5	,	,	PUNCT
dti-1367	71	6	kennedy	kennedy	PROPN
dti-1367	71	7	ad	ad	PROPN
dti-1367	71	8	,	,	PUNCT
dti-1367	71	9	williams	williams	PROPN
dti-1367	71	10	me	me	PROPN
dti-1367	71	11	,	,	PUNCT
dti-1367	71	12	lindofer	lindofer	PROPN
dti-1367	71	13	ma	ma	PROPN
dti-1367	71	14	,	,	PUNCT
dti-1367	71	15	taylor	taylor	PROPN
dti-1367	71	16	rp	rp	PROPN
dti-1367	71	17	.	.	PUNCT
dti-1367	72	1	the	the	DET
dti-1367	72	2	shaving	shaving	NOUN
dti-1367	72	3	reaction	reaction	NOUN
dti-1367	72	4	:	:	PUNCT
dti-1367	72	5	rituximab	rituximab	NOUN
dti-1367	72	6	/	/	SYM
dti-1367	72	7	cd20	cd20	PROPN
dti-1367	72	8	complexes	complex	NOUN
dti-1367	72	9	are	be	AUX
dti-1367	72	10	removed	remove	VERB
dti-1367	72	11	from	from	ADP
dti-1367	72	12	mantle	mantle	ADJ
dti-1367	72	13	cell	cell	NOUN
dti-1367	72	14	lymphoma	lymphoma	NOUN
dti-1367	72	15	and	and	CCONJ
dti-1367	72	16	chronic	chronic	ADJ
dti-1367	72	17	lymphocytic	lymphocytic	ADJ
dti-1367	72	18	leukemia	leukemia	NOUN
dti-1367	72	19	cells	cell	NOUN
dti-1367	72	20	by	by	ADP
dti-1367	72	21	thp-1	thp-1	SYM
dti-1367	72	22	monocytes	monocyte	NOUN
dti-1367	72	23	.	.	PUNCT
dti-1367	73	1	j	j	PROPN
dti-1367	73	2	immunol	immunol	NOUN
dti-1367	73	3	.	.	PUNCT
dti-1367	74	1	2006;176:2600–2609	2006;176:2600–2609	X
dti-1367	74	2	.	.	X
dti-1367	75	1	5	5	X
dti-1367	75	2	.	.	X
dti-1367	75	3	pedersen	pedersen	PROPN
dti-1367	75	4	ae	ae	PROPN
dti-1367	75	5	,	,	PUNCT
dti-1367	75	6	jungersen	jungersen	PROPN
dti-1367	75	7	mb	mb	PROPN
dti-1367	75	8	,	,	PUNCT
dti-1367	75	9	pedersen	pedersen	PROPN
dti-1367	75	10	cd	cd	PROPN
dti-1367	75	11	.	.	PROPN
dti-1367	75	12	monocytes	monocytes	AUX
dti-1367	75	13	mediate	mediate	VERB
dti-1367	75	14	shaving	shaving	NOUN
dti-1367	75	15	of	of	ADP
dti-1367	75	16	b	b	NOUN
dti-1367	75	17	-	-	PUNCT
dti-1367	75	18	cell	cell	NOUN
dti-1367	75	19	-	-	PUNCT
dti-1367	75	20	bound	bind	VERB
dti-1367	75	21	anti	anti	ADJ
dti-1367	75	22	-	-	ADJ
dti-1367	75	23	cd20	cd20	PROPN
dti-1367	75	24	antibodies	antibodie	VERB
dti-1367	75	25	.	.	PUNCT
dti-1367	76	1	immunology	immunology	NOUN
dti-1367	76	2	.	.	PUNCT
dti-1367	77	1	2011;133:239–245	2011;133:239–245	NUM
dti-1367	77	2	.	.	PUNCT
dti-1367	78	1	6	6	NUM
dti-1367	78	2	.	.	X
dti-1367	78	3	dass	dass	PROPN
dti-1367	78	4	s	s	PROPN
dti-1367	78	5	,	,	PUNCT
dti-1367	78	6	rawstron	rawstron	PROPN
dti-1367	78	7	ac	ac	PROPN
dti-1367	78	8	,	,	PUNCT
dti-1367	78	9	vital	vital	VERB
dti-1367	78	10	em	em	PRON
dti-1367	78	11	,	,	PUNCT
dti-1367	78	12	henshaw	henshaw	PROPN
dti-1367	78	13	k	k	PROPN
dti-1367	78	14	,	,	PUNCT
dti-1367	78	15	mcgonagle	mcgonagle	NOUN
dti-1367	78	16	d	d	NOUN
dti-1367	78	17	,	,	PUNCT
dti-1367	78	18	emery	emery	PROPN
dti-1367	78	19	p.	p.	PROPN
dti-1367	78	20	highly	highly	ADV
dti-1367	78	21	sensitive	sensitive	ADJ
dti-1367	78	22	b	b	NOUN
dti-1367	78	23	cell	cell	NOUN
dti-1367	78	24	analysis	analysis	NOUN
dti-1367	78	25	predicts	predict	VERB
dti-1367	78	26	response	response	NOUN
dti-1367	78	27	to	to	PART
dti-1367	78	28	rituximab	rituximab	VERB
dti-1367	78	29	therapy	therapy	NOUN
dti-1367	78	30	in	in	ADP
dti-1367	78	31	rheumatoid	rheumatoid	NOUN
dti-1367	78	32	arthritis	arthritis	NOUN
dti-1367	78	33	.	.	PUNCT
dti-1367	79	1	arthritis	arthritis	NOUN
dti-1367	79	2	rheum	rheum	NOUN
dti-1367	79	3	.	.	PUNCT
dti-1367	80	1	2008;58:2993–2999	2008;58:2993–2999	NOUN
dti-1367	80	2	.	.	PUNCT
dti-1367	81	1	7	7	X
dti-1367	81	2	.	.	X
dti-1367	81	3	leandro	leandro	PROPN
dti-1367	81	4	mj	mj	PROPN
dti-1367	81	5	,	,	PUNCT
dti-1367	81	6	cambridge	cambridge	PROPN
dti-1367	81	7	g	g	PROPN
dti-1367	81	8	,	,	PUNCT
dti-1367	81	9	ehrenstein	ehrenstein	PROPN
dti-1367	81	10	mr	mr	PROPN
dti-1367	81	11	,	,	PUNCT
dti-1367	81	12	edwards	edwards	PROPN
dti-1367	81	13	jc	jc	PROPN
dti-1367	81	14	.	.	PROPN
dti-1367	81	15	reconstitution	reconstitution	NOUN
dti-1367	81	16	of	of	ADP
dti-1367	81	17	peripheral	peripheral	ADJ
dti-1367	81	18	blood	blood	NOUN
dti-1367	81	19	b	b	NOUN
dti-1367	81	20	cells	cell	NOUN
dti-1367	81	21	after	after	ADP
dti-1367	81	22	depletion	depletion	NOUN
dti-1367	81	23	with	with	ADP
dti-1367	81	24	rituximab	rituximab	NOUN
dti-1367	81	25	in	in	ADP
dti-1367	81	26	patients	patient	NOUN
dti-1367	81	27	with	with	ADP
dti-1367	81	28	rheumatoid	rheumatoid	NOUN
dti-1367	81	29	arthritis	arthritis	NOUN
dti-1367	81	30	.	.	PUNCT
dti-1367	82	1	arthritis	arthritis	NOUN
dti-1367	82	2	rheum	rheum	NOUN
dti-1367	82	3	.	.	PUNCT
dti-1367	83	1	2006;54:613–620	2006;54:613–620	NUM
dti-1367	83	2	.	.	PUNCT
dti-1367	84	1	8	8	NUM
dti-1367	84	2	.	.	X
dti-1367	84	3	barra	barra	VERB
dti-1367	84	4	me	i	PRON
dti-1367	84	5	,	,	PUNCT
dti-1367	84	6	soni	soni	PROPN
dti-1367	84	7	d	d	PROPN
dti-1367	84	8	,	,	PUNCT
dti-1367	84	9	huy	huy	PROPN
dti-1367	84	10	vo	vo	PROPN
dti-1367	84	11	k	k	PROPN
dti-1367	84	12	,	,	PUNCT
dti-1367	84	13	chitnis	chitnis	PROPN
dti-1367	84	14	t	t	PROPN
dti-1367	84	15	,	,	PUNCT
dti-1367	85	1	stankiewicz	stankiewicz	PROPN
dti-1367	85	2	jm	jm	PROPN
dti-1367	85	3	.	.	PROPN
dti-1367	85	4	experience	experience	NOUN
dti-1367	85	5	with	with	ADP
dti-1367	85	6	long	long	ADJ
dti-1367	85	7	-	-	PUNCT
dti-1367	85	8	term	term	NOUN
dti-1367	85	9	rituximab	rituximab	NOUN
dti-1367	85	10	use	use	NOUN
dti-1367	85	11	in	in	ADP
dti-1367	85	12	a	a	DET
dti-1367	85	13	multiple	multiple	ADJ
dti-1367	85	14	sclerosis	sclerosis	NOUN
dti-1367	85	15	clinic	clinic	NOUN
dti-1367	85	16	[	[	X
dti-1367	85	17	published	publish	VERB
dti-1367	85	18	online	online	ADV
dti-1367	85	19	ahead	ahead	ADV
dti-1367	85	20	of	of	ADP
dti-1367	85	21	print	print	NOUN
dti-1367	85	22	october	october	PROPN
dti-1367	85	23	9	9	NUM
dti-1367	85	24	,	,	PUNCT
dti-1367	85	25	2016	2016	NUM
dti-1367	85	26	]	]	PUNCT
dti-1367	85	27	.	.	PUNCT
dti-1367	86	1	mult	mult	PROPN
dti-1367	86	2	scler	scler	PROPN
dti-1367	86	3	j	j	PROPN
dti-1367	86	4	exp	exp	NOUN
dti-1367	86	5	transl	transl	PROPN
dti-1367	86	6	and	and	CCONJ
dti-1367	86	7	clin	clin	PROPN
dti-1367	86	8	.	.	PUNCT
dti-1367	87	1	doi:10.1177/	doi:10.1177/	PROPN
dti-1367	87	2	2055217316672100	2055217316672100	NUM
dti-1367	87	3	.	.	PUNCT
dti-1367	88	1	9	9	X
dti-1367	88	2	.	.	X
dti-1367	88	3	jacob	jacob	PROPN
dti-1367	88	4	a	a	PRON
dti-1367	88	5	,	,	PUNCT
dti-1367	88	6	weinshenker	weinshenker	PROPN
dti-1367	88	7	bg	bg	PROPN
dti-1367	88	8	,	,	PUNCT
dti-1367	88	9	violich	violich	PROPN
dti-1367	88	10	i	i	PRON
dti-1367	88	11	,	,	PUNCT
dti-1367	88	12	et	et	PROPN
dti-1367	88	13	al	al	PROPN
dti-1367	88	14	.	.	PROPN
dti-1367	89	1	treatment	treatment	NOUN
dti-1367	89	2	of	of	ADP
dti-1367	89	3	neuromyelitis	neuromyelitis	PROPN
dti-1367	89	4	optica	optica	PROPN
dti-1367	89	5	with	with	ADP
dti-1367	89	6	rituximab	rituximab	NOUN
dti-1367	89	7	:	:	PUNCT
dti-1367	89	8	retrospective	retrospective	ADJ
dti-1367	89	9	analysis	analysis	NOUN
dti-1367	89	10	of	of	ADP
dti-1367	89	11	25	25	NUM
dti-1367	89	12	patients	patient	NOUN
dti-1367	89	13	.	.	PUNCT
dti-1367	90	1	arch	arch	ADJ
dti-1367	90	2	neurol	neurol	NOUN
dti-1367	90	3	.	.	PUNCT
dti-1367	91	1	2008;65	2008;65	NUM
dti-1367	91	2	:	:	PUNCT
dti-1367	91	3	1443–1448	1443–1448	NUM
dti-1367	91	4	.	.	PUNCT
dti-1367	91	5	10	10	NUM
dti-1367	91	6	.	.	PUNCT
dti-1367	92	1	greenberg	greenberg	PROPN
dti-1367	92	2	bm	bm	PROPN
dti-1367	92	3	,	,	PUNCT
dti-1367	92	4	graves	grave	NOUN
dti-1367	92	5	d	d	PROPN
dti-1367	92	6	,	,	PUNCT
dti-1367	92	7	remington	remington	PROPN
dti-1367	92	8	g	g	PROPN
dti-1367	92	9	,	,	PUNCT
dti-1367	92	10	et	et	PROPN
dti-1367	92	11	al	al	PROPN
dti-1367	92	12	.	.	PROPN
dti-1367	92	13	rituximab	rituximab	VERB
dti-1367	92	14	dosing	dose	VERB
dti-1367	92	15	and	and	CCONJ
dti-1367	92	16	monitoring	monitoring	NOUN
dti-1367	92	17	strategies	strategy	NOUN
dti-1367	92	18	in	in	ADP
dti-1367	92	19	neuromyelitis	neuromyelitis	PROPN
dti-1367	92	20	optica	optica	PROPN
dti-1367	92	21	patients	patient	NOUN
dti-1367	92	22	:	:	PUNCT
dti-1367	92	23	creating	create	VERB
dti-1367	92	24	strategies	strategy	NOUN
dti-1367	92	25	for	for	ADP
dti-1367	92	26	therapeutic	therapeutic	ADJ
dti-1367	92	27	success	success	NOUN
dti-1367	92	28	.	.	PUNCT
dti-1367	93	1	mult	mult	PROPN
dti-1367	93	2	scler	scler	PROPN
dti-1367	93	3	j.	j.	PROPN
dti-1367	93	4	2012;18:1022–1026	2012;18:1022–1026	PROPN
dti-1367	93	5	.	.	PUNCT
dti-1367	94	1	11	11	NUM
dti-1367	94	2	.	.	X
dti-1367	95	1	pellkofer	pellkofer	PROPN
dti-1367	95	2	hl	hl	NOUN
dti-1367	95	3	,	,	PUNCT
dti-1367	95	4	krumbholz	krumbholz	PROPN
dti-1367	95	5	m	m	PROPN
dti-1367	95	6	,	,	PUNCT
dti-1367	95	7	berthele	berthele	PROPN
dti-1367	95	8	a	a	PROPN
dti-1367	95	9	,	,	PUNCT
dti-1367	95	10	et	et	PROPN
dti-1367	96	1	al	al	PROPN
dti-1367	96	2	.	.	PUNCT
dti-1367	97	1	long	long	ADJ
dti-1367	97	2	term	term	NOUN
dti-1367	97	3	follow	follow	NOUN
dti-1367	97	4	-	-	PUNCT
dti-1367	97	5	up	up	NOUN
dti-1367	97	6	of	of	ADP
dti-1367	97	7	patients	patient	NOUN
dti-1367	97	8	with	with	ADP
dti-1367	97	9	neuromyelitis	neuromyelitis	PROPN
dti-1367	97	10	optica	optica	PROPN
dti-1367	97	11	after	after	ADP
dti-1367	97	12	repeated	repeat	VERB
dti-1367	97	13	therapy	therapy	NOUN
dti-1367	97	14	with	with	ADP
dti-1367	97	15	rituximab	rituximab	NOUN
dti-1367	97	16	.	.	PUNCT
dti-1367	98	1	neurol	neurol	NOUN
dti-1367	98	2	.	.	PUNCT
dti-1367	99	1	2011;76:1310–1315	2011;76:1310–1315	NUM
dti-1367	99	2	.	.	PUNCT
dti-1367	100	1	12	12	NUM
dti-1367	100	2	.	.	PUNCT
dti-1367	101	1	palanichamy	palanichamy	PROPN
dti-1367	101	2	a	a	PRON
dti-1367	101	3	,	,	PUNCT
dti-1367	101	4	jahn	jahn	NOUN
dti-1367	101	5	s	s	PROPN
dti-1367	101	6	,	,	PUNCT
dti-1367	101	7	nickles	nickle	NOUN
dti-1367	101	8	d	d	NOUN
dti-1367	101	9	,	,	PUNCT
dti-1367	101	10	et	et	PROPN
dti-1367	101	11	al	al	PROPN
dti-1367	101	12	.	.	PROPN
dti-1367	101	13	rituximab	rituximab	NOUN
dti-1367	101	14	efficiently	efficiently	ADV
dti-1367	101	15	depletes	deplete	VERB
dti-1367	101	16	increased	increase	VERB
dti-1367	101	17	cd20	cd20	PROPN
dti-1367	101	18	-	-	PUNCT
dti-1367	101	19	expressing	express	VERB
dti-1367	101	20	t	t	NOUN
dti-1367	101	21	cells	cell	NOUN
dti-1367	101	22	in	in	ADP
dti-1367	101	23	multiple	multiple	ADJ
dti-1367	101	24	sclerosis	sclerosis	NOUN
dti-1367	101	25	patients	patient	NOUN
dti-1367	101	26	.	.	PUNCT
dti-1367	102	1	j	j	PROPN
dti-1367	102	2	of	of	ADP
dti-1367	102	3	immunol	immunol	NOUN
dti-1367	102	4	.	.	PUNCT
dti-1367	103	1	2014;193:580–586	2014;193:580–586	NUM
dti-1367	103	2	.	.	PUNCT
dti-1367	104	1	figure	figure	NOUN
dti-1367	104	2	2	2	NUM
dti-1367	104	3	.	.	PUNCT
dti-1367	105	1	median	median	PROPN
dti-1367	105	2	b	b	X
dti-1367	105	3	-	-	PUNCT
dti-1367	105	4	cell	cell	NOUN
dti-1367	105	5	count	count	NOUN
dti-1367	105	6	in	in	ADP
dti-1367	105	7	study	study	NOUN
dti-1367	105	8	wa25046	wa25046	PROPN
dti-1367	105	9	(	(	PUNCT
dti-1367	105	10	primary	primary	ADJ
dti-1367	105	11	-	-	PUNCT
dti-1367	105	12	progressive	progressive	ADJ
dti-1367	105	13	multiple	multiple	ADJ
dti-1367	105	14	sclerosis	sclerosis	NOUN
dti-1367	105	15	)	)	PUNCT
dti-1367	105	16	.	.	PUNCT
dti-1367	106	1	ocr	ocr	PROPN
dti-1367	106	2	indicates	indicate	VERB
dti-1367	106	3	ocrelizumab	ocrelizumab	NOUN
dti-1367	106	4	.	.	PUNCT